<?xml version="1.0" encoding="utf-8"?>
<refworks xmlns:refworks="www.refworks.com/xml/">
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1849</id>
<a1>Beaton,A.</a1>
<a1>Palumbo,P.</a1>
<a1>Berns,K. I.</a1>
<t1>Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1989</yr>
<fd>Oct</fd>
<vo>63</vo>
<is>10</is>
<sp>4450</sp>
<op>4454</op>
<k1>Chloramphenicol O-Acetyltransferase/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Gene Expression Regulation</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Transcription, Genetic</k1>
<k1>Viral Proteins/physiology</k1>
<ab>The leftward two promoters of the adeno-associated virus (AAV) 2 genome were fused to reporter genes, and the constructs were used to transfect HeLa cells. The promoters functioned constitutively but were repressed in trans by the AAV rep gene product(s). The repression was relieved by adenovirus infection. Evidence which indicated an enhancer function for the inverted terminal repeat of the AAV-2 genome was also obtained.</ab>
<no>LR: 20091118; GR: AI-22251/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (Viral Proteins); EC 2.3.1.28 (Chloramphenicol O-Acetyltransferase); OID: NLM: PMC251068; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York 10021.</ad>
<an>PMID: 2550677</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2550677</pmid>
<pmcid>PMC251068</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1820</id>
<a1>Berns,K. I.</a1>
<t1>The Gordon Wilson Lecture. From basic virology to human gene therapy</t1>
<jf>Transactions of the American Clinical and Climatological Association</jf>
<jo>Trans.Am.Clin.Climatol.Assoc.</jo>
<yr>1999</yr>
<vo>110</vo>
<sp>75</sp>
<op>85</op>
<k1>Base Sequence</k1>
<k1>DNA, Viral/chemistry/genetics</k1>
<k1>Dependovirus/genetics/growth &amp; development</k1>
<k1>Gene Therapy</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Models, Genetic</k1>
<k1>Molecular Sequence Data</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Parvoviridae/genetics</k1>
<k1>Terminal Repeat Sequences</k1>
<k1>Virology</k1>
<no>LR: 20091118; JID: 7507559; 0 (DNA, Viral); RF: 22; OID: NLM: PMC2194317; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0065-7778; 0065-7778</sn>
<ad>College of Medicine, Gainesville, FL 32610-0014, USA.</ad>
<an>PMID: 10344008</an>
<la>eng</la>
<sf>Lectures; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>10344008</pmid>
<pmcid>PMC2194317</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1830</id>
<a1>Berns,K. I.</a1>
<t1>Preventing academic medical center from becoming an oxymoron</t1>
<jf>Academic medicine : journal of the Association of American Medical Colleges</jf>
<jo>Acad.Med.</jo>
<yr>1996</yr>
<fd>Feb</fd>
<vo>71</vo>
<is>2</is>
<sp>117</sp>
<op>120</op>
<k1>Academic Medical Centers/economics/organization &amp; administration/standards/trends</k1>
<k1>Biological Science Disciplines</k1>
<k1>Costs and Cost Analysis</k1>
<k1>Curriculum</k1>
<k1>Delivery of Health Care</k1>
<k1>Education, Medical/economics</k1>
<k1>Faculty, Medical</k1>
<k1>Financing, Organized</k1>
<k1>Forecasting</k1>
<k1>Hospitals, Teaching/economics</k1>
<k1>Humans</k1>
<k1>Interprofessional Relations</k1>
<k1>Organizational Objectives</k1>
<k1>Research/education</k1>
<k1>Research Support as Topic</k1>
<k1>Schools, Medical</k1>
<k1>Societies</k1>
<k1>United States</k1>
<ab>Many academic medical institutions are facing serious threats to their survival today as changes in the organization and financing of health care delivery and reductions in federal support create damaging pressures. In order for Americans to continue to have the best health care in the world, academic medicine and its crucial contributions of medical education, training, and research must receive adequate support. The author maintains that it is up to the Association of American Medical Colleges and associated organizations to ensure that this message is heard and recognized and to seek an all-payer approach that would support the costs associated with medical education and training and would allow teaching hospitals to compete on a level playing field with non-teaching hospitals. Academic medical institutions must face painful transformations while maintaining their academic missions; the author discusses the nature of these transformations and missions, particularly research, and outlines useful strategies to maintain these missions, such as establishing a centralized approach to curriculum and having clinical and basic science faculty form alliances to address common research problems and secure more research funding. He concludes that many of the structural and other changes that academic medicine&amp;#39;s institutions must make may result in true improvements and help maintain the validity of the term academic medical center in the future.</ab>
<no>LR: 20081121; JID: 8904605; ppublish</no>
<pp>UNITED STATES</pp>
<sn>1040-2446; 1040-2446</sn>
<ad>Department of Microbiology, Cornell University Medical College, New York, NY 10021, USA.</ad>
<an>PMID: 8615921</an>
<la>eng</la>
<sf>Journal Article; AIM; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8615921</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1847</id>
<a1>Berns,K. I.</a1>
<t1>Parvovirus replication</t1>
<jf>Microbiological reviews</jf>
<jo>Microbiol.Rev.</jo>
<yr>1990</yr>
<fd>Sep</fd>
<vo>54</vo>
<is>3</is>
<sp>316</sp>
<op>329</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>DNA Replication</k1>
<k1>Gene Expression Regulation, Viral</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Parvoviridae/genetics/physiology</k1>
<k1>Viral Proteins/genetics</k1>
<k1>Virus Replication</k1>
<ab>The members of the family Parvoviridae are among the smallest of the DNA viruses, with a linear single-stranded genome of about 5 kilobases. Currently the family is divided into three genera, two of which contain viruses of vertebrates and a third containing insect viruses. This review concentrates on the vertebrate viruses, with emphasis on recent advances in our insights into the molecular biology of viral replication. Traditionally the vertebrate viruses have been distinguished by the presence or absence of a requirement for a coinfection with a helper virus before productive infection can occur, hence the notion that the dependoviruses (adeno-associated viruses [AAV]) are defective. Recent data would suggest that not only is there a great deal of structural and genetic organizational similarity between the two types of vertebrate viruses, but also there is significant similarity in the molecular biology of productive replication. What differs is the physiological condition of the host cell that renders it permissive. Healthy dividing cells are permissive for productive replication by autonomous parvoviruses; such cells result in latent infection by dependoviruses. For a cell to become permissive for productive AAV replication, it must have been exposed to toxic conditions which activate a latent AAV genome. Such conditions can be caused by helper-virus infection or exposure to physical (UV light) or chemical (some carcinogens) agents. In this paper the molecular biology of replication is reviewed, with special emphasis on the role of the host and the consequences of viral infection for the host.</ab>
<no>LR: 20091118; GR: AI-22251/AI/NIAID NIH HHS/United States; GR: AI-26122/AI/NIAID NIH HHS/United States; JID: 7806086; 0 (Viral Proteins); RF: 153; OID: NLM: PMC372780; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0146-0749; 0146-0749</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 2215424</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2215424</pmid>
<pmcid>PMC372780</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1888</id>
<a1>Berns,K. I.</a1>
<t1>Molecular biology of the adeno-associated viruses</t1>
<jf>Current topics in microbiology and immunology</jf>
<jo>Curr.Top.Microbiol.Immunol.</jo>
<yr>1974</yr>
<vo>65</vo>
<sp>1</sp>
<op>20</op>
<k1>Adenoviridae/metabolism</k1>
<k1>Adsorption</k1>
<k1>Base Sequence</k1>
<k1>Bromodeoxyuridine/metabolism</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>DNA, Circular</k1>
<k1>DNA, Single-Stranded</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>Defective Viruses</k1>
<k1>Helper Viruses</k1>
<k1>Microscopy, Electron</k1>
<k1>Molecular Weight</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Nucleic Acid Hybridization</k1>
<k1>Phosphorus Radioisotopes</k1>
<k1>Protein Conformation</k1>
<k1>RNA, Viral/biosynthesis</k1>
<k1>Tritium</k1>
<k1>Viral Proteins/biosynthesis</k1>
<k1>Virus Replication</k1>
<no>LR: 20061115; JID: 0110513; 0 (DNA, Circular); 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (Phosphorus Radioisotopes); 0 (RNA, Viral); 0 (Viral Proteins); 10028-17-8 (Tritium); 59-14-3 (Bromodeoxyuridine); RF: 64; ppublish</no>
<pp>GERMANY, WEST</pp>
<sn>0070-217X; 0070-217X</sn>
<an>PMID: 4613539</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>4613539</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1890</id>
<a1>Berns,K. I.</a1>
<a1>Adler,S.</a1>
<t1>Separation of two types of adeno-associated virus particles containing complementary polynucleotide chains</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1972</yr>
<fd>Feb</fd>
<vo>9</vo>
<is>2</is>
<sp>394</sp>
<op>396</op>
<k1>Adenoviridae/analysis</k1>
<k1>Bromodeoxyuridine/metabolism</k1>
<k1>Carcinoma</k1>
<k1>Cell Line</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>DNA, Single-Stranded/analysis</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Helper Viruses</k1>
<k1>Humans</k1>
<k1>Methods</k1>
<k1>Mouth Neoplasms</k1>
<k1>Nucleic Acid Denaturation</k1>
<k1>Nucleic Acid Renaturation</k1>
<k1>Phosphorus Isotopes</k1>
<k1>Polynucleotides/analysis</k1>
<k1>Tritium</k1>
<ab>An adeno-associated virus containing bromodeoxyuridine-substituted deoxyribonucleic acid has been fractionated by equilibrium centrifugation in CsCl into two classes of virions which contain complementary polynucleotide chains.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (Phosphorus Isotopes); 0 (Polynucleotides); 10028-17-8 (Tritium); 59-14-3 (Bromodeoxyuridine); OID: NLM: PMC356306; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 5014934</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>5014934</pmid>
<pmcid>PMC356306</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1822</id>
<a1>Berns,K. I.</a1>
<a1>Atlas,R. M.</a1>
<a1>Cassell,G.</a1>
<a1>Shoemaker,J.</a1>
<t1>Preventing the misuse of microorganisms: the role of the American Society for Microbiology in protecting against biological weapons</t1>
<jf>Critical reviews in microbiology</jf>
<jo>Crit.Rev.Microbiol.</jo>
<yr>1998</yr>
<vo>24</vo>
<is>3</is>
<sp>273</sp>
<op>280</op>
<k1>Biological Warfare/legislation &amp; jurisprudence</k1>
<k1>History, 20th Century</k1>
<k1>International Cooperation</k1>
<k1>Microbiology/history</k1>
<k1>Societies, Scientific/history</k1>
<k1>United States</k1>
<ab>The American Society for Microbiology&amp;#39;s (ASM) involvement with issues surrounding biological weapons began during World War II and continues to the present time. The Public and Scientific Affairs Board (PSAB) of the ASM has played an important role in monitoring and responding to legislative and regulatory issues involving biological weapons. As this review makes apparent, there is no consensus of opinion among scientists on their role in biological defense research, or is it likely that there will ever be complete agreement. There is consensus that steps should be taken to prevent biological warfare and that openness of scientific research and global surveillance of disease outbreaks can significantly increase transparency for detecting development of biological weapons. The ASM recommends increased attention to and efforts directed toward global surveillance of disease outbreaks, not only to aid public health organizations in improving human health, but also to establish baseline data against which unusual disease outbreaks can be assessed. Issues of how best to increase global security and to achieve a scientifically based verification protocol of the Biological Weapons Convention are important and continue to be addressed by the ASM.</ab>
<no>LR: 20041117; JID: 8914274; ppublish</no>
<pp>UNITED STATES</pp>
<sn>1040-841X; 1040-841X</sn>
<ad>American Society for Microbiology, Washington, DC 20005-4171, USA.</ad>
<an>PMID: 9800104</an>
<la>eng</la>
<sf>Historical Article; Journal Article; IM; Q</sf>
<do>10.1080/10408419891294226</do>
<ol>Unknown(0)</ol>
<pmid>9800104</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1857</id>
<a1>Berns,K. I.</a1>
<a1>Bohenzky,R. A.</a1>
<t1>Adeno-associated viruses: an update</t1>
<jf>Advances in Virus Research</jf>
<jo>Adv.Virus Res.</jo>
<yr>1987</yr>
<vo>32</vo>
<sp>243</sp>
<op>306</op>
<k1>Adenoviridae/genetics</k1>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>Cloning, Molecular/methods</k1>
<k1>DNA Repair</k1>
<k1>DNA Replication</k1>
<k1>DNA, Single-Stranded/genetics</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/physiology/ultrastructure</k1>
<k1>Gene Expression Regulation</k1>
<k1>Genes, Viral</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Neoplasms, Experimental/microbiology</k1>
<k1>Transcription, Genetic</k1>
<k1>Viral Proteins/genetics</k1>
<k1>Virus Replication</k1>
<no>LR: 20071114; GR: AI-07110-05/AI/NIAID NIH HHS/United States; GR: AI-22251/AI/NIAID NIH HHS/United States; JID: 0370441; 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (Viral Proteins); RF: 265; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0065-3527; 0065-3527</sn>
<an>PMID: 3039813</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>3039813</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1831</id>
<a1>Berns,K. I.</a1>
<a1>Giraud,C.</a1>
<t1>Biology of adeno-associated virus</t1>
<jf>Current topics in microbiology and immunology</jf>
<jo>Curr.Top.Microbiol.Immunol.</jo>
<yr>1996</yr>
<vo>218</vo>
<sp>1</sp>
<op>23</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>DNA, Viral</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Gene Therapy</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Parvoviridae Infections/virology</k1>
<k1>Virus Latency</k1>
<k1>Virus Replication</k1>
<no>LR: 20060421; JID: 0110513; 0 (DNA, Viral); RF: 124; ppublish</no>
<pp>GERMANY</pp>
<sn>0070-217X; 0070-217X</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York 10021, USA.</ad>
<an>PMID: 8794242</an>
<la>eng</la>
<sf>Journal Article; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8794242</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1832</id>
<a1>Berns,K. I.</a1>
<a1>Giraud,C.</a1>
<t1>Adenovirus and adeno-associated virus as vectors for gene therapy</t1>
<jf>Annals of the New York Academy of Sciences</jf>
<jo>Ann.N.Y.Acad.Sci.</jo>
<yr>1995</yr>
<fd>Nov 27</fd>
<vo>772</vo>
<sp>95</sp>
<op>104</op>
<k1>Adenoviridae/genetics/physiology</k1>
<k1>DNA, Recombinant</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Defective Viruses/genetics/physiology</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Gene Therapy</k1>
<k1>Genetic Vectors</k1>
<k1>Recombinant Fusion Proteins/genetics/immunology</k1>
<k1>Vaccines, Synthetic</k1>
<k1>Virus Integration</k1>
<k1>Virus Replication</k1>
<no>LR: 20071114; GR: A122251/PHS HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 7506858; 0 (DNA, Recombinant); 0 (DNA, Viral); 0 (Recombinant Fusion Proteins); 0 (Vaccines, Synthetic); RF: 48; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0077-8923; 0077-8923</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA.</ad>
<an>PMID: 8546417</an>
<la>eng</la>
<sf>Comparative Study; Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8546417</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1878</id>
<a1>Berns,K. I.</a1>
<a1>Hauswirth,W. W.</a1>
<t1>Adeno-associated viruses</t1>
<jf>Advances in Virus Research</jf>
<jo>Adv.Virus Res.</jo>
<yr>1979</yr>
<vo>25</vo>
<sp>407</sp>
<op>449</op>
<k1>Antigens, Viral/analysis</k1>
<k1>Base Sequence</k1>
<k1>Cell Transformation, Neoplastic</k1>
<k1>Cell Transformation, Viral</k1>
<k1>DNA, Viral/analysis/biosynthesis</k1>
<k1>Dependovirus/analysis/physiology</k1>
<k1>Helper Viruses/physiology</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Protein Biosynthesis</k1>
<k1>RNA, Viral/biosynthesis</k1>
<k1>Transcription, Genetic</k1>
<k1>Viral Proteins/analysis</k1>
<no>LR: 20061115; JID: 0370441; 0 (Antigens, Viral); 0 (DNA, Viral); 0 (RNA, Viral); 0 (Viral Proteins); RF: 175; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0065-3527; 0065-3527</sn>
<an>PMID: 230727</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>230727</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1879</id>
<a1>Berns,K. I.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Fife,K. H.</a1>
<a1>Lusby,E.</a1>
<t1>Adeno-associated virus DNA replication</t1>
<jf>Cold Spring Harbor symposia on quantitative biology</jf>
<jo>Cold Spring Harb.Symp.Quant.Biol.</jo>
<yr>1979</yr>
<vo>43 Pt 2</vo>
<sp>781</sp>
<op>787</op>
<k1>Adenoviruses, Human/genetics</k1>
<k1>Base Sequence</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Virus Replication</k1>
<no>LR: 20061115; GENBANK/M10681; JID: 1256107; 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0091-7451; 0091-7451</sn>
<an>PMID: 226321</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>226321</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1887</id>
<a1>Berns,K. I.</a1>
<a1>Kelly,T. J.,Jr</a1>
<t1>Letter: Visualization of the inverted terminal repetition in adeno-associated virus DNA</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1974</yr>
<fd>Jan 15</fd>
<vo>82</vo>
<is>2</is>
<sp>267</sp>
<op>271</op>
<k1>Adenoviridae</k1>
<k1>Base Sequence</k1>
<k1>Bromodeoxyuridine</k1>
<k1>Carbon Radioisotopes</k1>
<k1>DNA Viruses</k1>
<k1>DNA, Circular</k1>
<k1>DNA, Single-Stranded</k1>
<k1>DNA, Viral</k1>
<k1>Microscopy, Electron</k1>
<k1>Models, Structural</k1>
<k1>Thymidine/metabolism</k1>
<no>LR: 20010323; JID: 2985088R; 0 (Carbon Radioisotopes); 0 (DNA, Circular); 0 (DNA, Single-Stranded); 0 (DNA, Viral); 50-89-5 (Thymidine); 59-14-3 (Bromodeoxyuridine); ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 4816655</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>4816655</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1885</id>
<a1>Berns,K. I.</a1>
<a1>Kort,J.</a1>
<a1>Fife,K. H.</a1>
<a1>Grogan,E. W.</a1>
<a1>Spear,I.</a1>
<t1>Study of the fine structure of adeno-associated virus DNA with bacterial restriction endonucleases</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1975</yr>
<fd>Sep</fd>
<vo>16</vo>
<is>3</is>
<sp>712</sp>
<op>719</op>
<k1>Base Sequence</k1>
<k1>Chromosomes/analysis</k1>
<k1>DNA Restriction Enzymes/metabolism</k1>
<k1>DNA, Viral/analysis/metabolism</k1>
<k1>Endonucleases/metabolism</k1>
<k1>Molecular Weight</k1>
<k1>Satellite Viruses/analysis/metabolism</k1>
<ab>A physical map of the adeno-associated virus type 2 genome has been constructed on the basis of the five fragments produced by the restriction endonucleases HindII + III from Hemophilus influenzae. There are three endo R-HindII cleavage sites and one endo R-HindIII site. Evidence has been obtained to support the existence of two nucleotide sequence permutations in adeno-associated virus DNA, the start points of which have been estimated to be separated by 1% of the genome. The three cleavage fragments produced by endo R-Eco RI have been ordered and oriented with respect to the endo R-HindII + III cleavage map.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Viral); EC 3.1.- (Endonucleases); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC354719; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 1159899</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1159899</pmid>
<pmcid>PMC354719</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1852</id>
<a1>Berns,K. I.</a1>
<a1>Kotin,R. M.</a1>
<a1>Labow,M. A.</a1>
<t1>Regulation of adeno-associated virus DNA replication</t1>
<jf>Biochimica et biophysica acta</jf>
<jo>Biochim.Biophys.Acta</jo>
<yr>1988</yr>
<fd>Dec 20</fd>
<vo>951</vo>
<is>2-3</is>
<sp>425</sp>
<op>429</op>
<k1>Base Sequence</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Gene Expression Regulation</k1>
<k1>Molecular Sequence Data</k1>
<k1>Simian virus 40/genetics</k1>
<k1>Virus Replication</k1>
<no>LR: 20071114; GR: AI 22251/AI/NIAID NIH HHS/United States; GR: AI 26122/AI/NIAID NIH HHS/United States; JID: 0217513; 0 (DNA, Viral); RF: 20; ppublish</no>
<pp>NETHERLANDS</pp>
<sn>0006-3002; 0006-3002</sn>
<ad>Department of Microbiology, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 2850017</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2850017</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1856</id>
<a1>Berns,K. I.</a1>
<a1>Labow,M. A.</a1>
<t1>Parvovirus gene regulation</t1>
<jf>The Journal of general virology</jf>
<jo>J.Gen.Virol.</jo>
<yr>1987</yr>
<fd>Mar</fd>
<vo>68 ( Pt 3)</vo>
<is>Pt 3</is>
<sp>601</sp>
<op>614</op>
<k1>Animals</k1>
<k1>DNA Replication</k1>
<k1>Gene Expression Regulation</k1>
<k1>Genes, Viral</k1>
<k1>Humans</k1>
<k1>Parvoviridae/genetics</k1>
<k1>Transcription, Genetic</k1>
<no>LR: 20071114; GR: 22251/PHS HHS/United States; JID: 0077340; RF: 99; ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-1317; 0022-1317</sn>
<an>PMID: 3546593</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>3546593</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1836</id>
<a1>Berns,K. I.</a1>
<a1>Linden,R. M.</a1>
<t1>The cryptic life style of adeno-associated virus</t1>
<jf>BioEssays : news and reviews in molecular, cellular and developmental biology</jf>
<jo>Bioessays</jo>
<yr>1995</yr>
<fd>Mar</fd>
<vo>17</vo>
<is>3</is>
<sp>237</sp>
<op>245</op>
<k1>Base Sequence</k1>
<k1>Dependovirus/genetics/pathogenicity</k1>
<k1>Genetic Vectors</k1>
<k1>Genome, Viral</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Virulence</k1>
<ab>Although 80-90% of adults are seropositive for antibodies against the human parvovirus adeno-associated virus (AAV), infection has not been associated with either symptoms or disease. In cell culture, AAV infection is not productive unless there is a coinfection with a helper virus, either adenovirus or any type of herpes virus; in the absence of a helper virus coinfection the viral genome is integrated into the genome, usually at a specific site on chromosome 19q13.3-qter. The integrated genome can be activated and rescued by subsequent super infection by a helper virus. The high frequency of site-specific integration by AAV and the lack of associated disease have encouraged the use of AAV as a vector for gene therapy. This review will focus on the molecular mechanisms involved in the establishment of, and rescue from, the latent state and their relevance to use of AAV as a vector.</ab>
<no>LR: 20071114; GR: AI22251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 8510851; RF: 61; ppublish</no>
<pp>ENGLAND</pp>
<sn>0265-9247; 0265-9247</sn>
<ad>Dept of Microbiology, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 7748178</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<do>10.1002/bies.950170310</do>
<ol>Unknown(0)</ol>
<pmid>7748178</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1813</id>
<a1>Berns,K. I.</a1>
<a1>Meneses,P.</a1>
<a1>Duvoisin,R.</a1>
<a1>Laipis,P.</a1>
<a1>Hauswirth,W.</a1>
<t1>Use of recombinant angiostatin to prevent retinal neovascularization</t1>
<jf>Transactions of the American Clinical and Climatological Association</jf>
<jo>Trans.Am.Clin.Climatol.Assoc.</jo>
<yr>2001</yr>
<vo>112</vo>
<sp>68</sp>
<op>75; discussion 75-6</op>
<k1>Angiostatins</k1>
<k1>Animals</k1>
<k1>Animals, Newborn</k1>
<k1>Disease Models, Animal</k1>
<k1>Humans</k1>
<k1>Infant, Newborn</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Peptide Fragments/genetics/pharmacology</k1>
<k1>Plasmids/genetics</k1>
<k1>Plasminogen/genetics/pharmacology</k1>
<k1>Rats</k1>
<k1>Recombinant Proteins/genetics/pharmacology</k1>
<k1>Retinal Neovascularization/prevention &amp; control</k1>
<k1>Retinopathy of Prematurity/prevention &amp; control</k1>
<no>LR: 20091118; GR: AI22251/AI/NIAID NIH HHS/United States; GR: EY13101/EY/NEI NIH HHS/United States; JID: 7507559; 0 (Peptide Fragments); 0 (Recombinant Proteins); 0 (recombinant kringle 1-3 (rKI-3) of human plasminogen); 86090-08-6 (Angiostatins); 9001-91-6 (Plasminogen); OID: NLM: PMC2194395; ppublish</no>
<pp>United States</pp>
<sn>0065-7778; 0065-7778</sn>
<ad>Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, USA.</ad>
<an>PMID: 11413784</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>11413784</pmid>
<pmcid>PMC2194395</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1884</id>
<a1>Berns,K. I.</a1>
<a1>Pinkerton,T. C.</a1>
<a1>Thomas,G. F.</a1>
<a1>Hoggan,M. D.</a1>
<t1>Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1975</yr>
<fd>Dec</fd>
<vo>68</vo>
<is>2</is>
<sp>556</sp>
<op>560</op>
<k1>Adenoviridae/growth &amp; development</k1>
<k1>Antigens, Viral/analysis</k1>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>DNA/analysis</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Helper Viruses/growth &amp; development</k1>
<k1>Nucleotides/analysis</k1>
<k1>Satellite Viruses/analysis/growth &amp; development/immunology</k1>
<k1>Virus Replication</k1>
<no>LR: 20001218; JID: 0110674; 0 (Antigens, Viral); 0 (DNA, Viral); 0 (Nucleotides); 9007-49-2 (DNA); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 1198930</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1198930</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1891</id>
<a1>Berns,K. I.</a1>
<a1>Rose,J. A.</a1>
<t1>Evidence for a single-stranded adenovirus-associated virus genome: isolation and separation of complementary single strands</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1970</yr>
<fd>Jun</fd>
<vo>5</vo>
<is>6</is>
<sp>693</sp>
<op>699</op>
<k1>Adenoviridae/growth &amp; development/isolation &amp; purification</k1>
<k1>Alkalies</k1>
<k1>Bromodeoxyuridine</k1>
<k1>Carbon Isotopes</k1>
<k1>Carcinoma</k1>
<k1>Cell Line</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>Cesium</k1>
<k1>Chlorides</k1>
<k1>Citrates</k1>
<k1>DNA, Viral/isolation &amp; purification</k1>
<k1>Genetics, Microbial</k1>
<k1>Hot Temperature</k1>
<k1>Humans</k1>
<k1>Molecular Biology</k1>
<k1>Mouth Neoplasms</k1>
<k1>Nucleic Acid Denaturation</k1>
<k1>Sodium</k1>
<k1>Sodium Chloride</k1>
<k1>Sucrose</k1>
<k1>Sulfates</k1>
<k1>Thymidine</k1>
<k1>Tritium</k1>
<ab>Single-stranded adenovirus-associated virus type 2 deoxyribonucleic acid (AAV-2 DNA) has been isolated from the virion after enzymatic pretreatment of the particles by heating at 53 C for 1 hr in 0.015 m NaCl plus 0.0015 m sodium citrate in the presence of 1% sodium dodecyl sulfate. Double-stranded AAV-2 DNA present as a marker is not denatured by this treatment. AAV-2 single-stranded DNA is composed of two complementary species which can be separated in neutral CsCl when 5-bromodeoxyuridine has been substituted for thymidine in the DNA. The present report is the first documented instance of the separation of complementary strands of an animal virus DNA.</ab>
<no>LR: 20091118; JID: 0113724; 0 (Alkalies); 0 (Carbon Isotopes); 0 (Chlorides); 0 (Citrates); 0 (DNA, Viral); 0 (Sulfates); 10028-17-8 (Tritium); 50-89-5 (Thymidine); 57-50-1 (Sucrose); 59-14-3 (Bromodeoxyuridine); 7440-23-5 (Sodium); 7440-46-2 (Cesium); 7647-14-5 (Sodium Chloride); OID: NLM: PMC376062; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 5429749</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>5429749</pmid>
<pmcid>PMC376062</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1892</id>
<a1>Berns,K. I.</a1>
<a1>Silverman,C.</a1>
<t1>Natural occurrence of cross-linked vaccinia virus deoxyribonucleic acid</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1970</yr>
<fd>Mar</fd>
<vo>5</vo>
<is>3</is>
<sp>299</sp>
<op>304</op>
<k1>Apatites</k1>
<k1>Carbon Isotopes</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>Cesium</k1>
<k1>Chlorides</k1>
<k1>Chromatography</k1>
<k1>Coliphages/analysis</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Molecular Weight</k1>
<k1>Sucrose</k1>
<k1>Thymidine</k1>
<k1>Tritium</k1>
<k1>Vaccinia virus/analysis/growth &amp; development</k1>
<ab>The molecular weight of native vaccinia deoxyribonucleic acid (DNA) is 1 to 1.17 times that of native T4 DNA. Sedimentation of denatured vaccinia DNA through alkaline sucrose gradients yields an apparent molecular weight greater than twice that of denatured T4 DNA, implying that the complementary strands of vaccinia DNA do not separate upon denaturation. When alkali-denatured vaccinia DNA is neutralized, it has the physical chemical properties of native DNA when tested by sedimentation through neutral sucrose gradients, banding in CsCl, and by hydroxylapatite chromatography. We conclude that almost all mature vaccinia DNA molecules contain a small number of naturally occurring cross-links.</ab>
<no>LR: 20091118; JID: 0113724; 0 (Apatites); 0 (Carbon Isotopes); 0 (Chlorides); 0 (DNA, Viral); 10028-17-8 (Tritium); 50-89-5 (Thymidine); 57-50-1 (Sucrose); 7440-46-2 (Cesium); OID: NLM: PMC376005; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 5438108</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>5438108</pmid>
<pmcid>PMC376005</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1894</id>
<a1>Berns,K. I.</a1>
<a1>Silverman,C.</a1>
<a1>Weissbach,A.</a1>
<t1>Separation of a new deoxyribonucleic acid polymerase from vaccinia-infected HeLa cells</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1969</yr>
<fd>Jul</fd>
<vo>4</vo>
<is>1</is>
<sp>15</sp>
<op>23</op>
<k1>Chloromercuribenzoates/pharmacology</k1>
<k1>Chromatography</k1>
<k1>DNA/pharmacology</k1>
<k1>DNA Nucleotidyltransferases/isolation &amp; purification</k1>
<k1>DNA, Viral/pharmacology</k1>
<k1>Hela Cells/enzymology</k1>
<k1>Hot Temperature</k1>
<k1>Hydrogen-Ion Concentration</k1>
<k1>Immune Sera/pharmacology</k1>
<k1>Vaccinia virus/enzymology</k1>
<ab>HeLa cell deoxyribonucleic acid (DNA) polymerase was purified about 100-fold by sequential column chromatography on phosphocellulose, hydroxylapatite, and Bio Rex 70. A new form of DNA polymerase found in vaccinia virus-infected cells was separated from HeLa DNA polymerase by chromatography on diethylamino-ethyl cellulose. The new form was also purified approximately 100-fold in the same manner as the HeLa DNA polymerase. In addition to chromatographic differences, the two enzymes differed with regard to primer response, relative activity at high pH, inactivation by heat and p-chloromercuribenzoate, and inhibition by vaccinia antiserum.</ab>
<no>LR: 20091118; JID: 0113724; 0 (Chloromercuribenzoates); 0 (DNA, Viral); 0 (Immune Sera); 9007-49-2 (DNA); EC 2.7.7.- (DNA Nucleotidyltransferases); OID: NLM: PMC375832; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 5804948</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>5804948</pmid>
<pmcid>PMC375832</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1895</id>
<a1>BERNS,K. I.</a1>
<a1>THOMAS,C. A.,Jr</a1>
<t1>Isolation of High Molecular Weight Dna from Hemophilus Influenzae</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1965</yr>
<fd>Mar</fd>
<vo>11</vo>
<sp>476</sp>
<op>490</op>
<k1>Amino Acids</k1>
<k1>Biochemical Phenomena</k1>
<k1>Biochemistry</k1>
<k1>Carbon Isotopes</k1>
<k1>Cell Nucleus</k1>
<k1>Colorimetry</k1>
<k1>DNA, Bacterial</k1>
<k1>Escherichia coli</k1>
<k1>Haemophilus influenzae</k1>
<k1>Molecular Weight</k1>
<k1>Photomicrography</k1>
<k1>RNA, Bacterial</k1>
<k1>Research</k1>
<k1>Serratia marcescens</k1>
<k1>Spectrophotometry</k1>
<k1>Tritium</k1>
<k1>Ultracentrifugation</k1>
<k1>EXPERIMENTAL LAB STUDY</k1>
<no>LR: 20081121; JID: 2985088R; 0 (Amino Acids); 0 (Carbon Isotopes); 0 (DNA, Bacterial); 0 (RNA, Bacterial); 10028-17-8 (Tritium); OTO: NLM; ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 14267270</an>
<la>eng</la>
<sf>Journal Article; OM</sf>
<ol>Unknown(0)</ol>
<pmid>14267270</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1851</id>
<a1>Bohenzky,R. A.</a1>
<a1>Berns,K. I.</a1>
<t1>Interactions between the termini of adeno-associated virus DNA</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1989</yr>
<fd>Mar 5</fd>
<vo>206</vo>
<is>1</is>
<sp>91</sp>
<op>100</op>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Chimera</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Models, Genetic</k1>
<k1>Molecular Sequence Data</k1>
<k1>Mutation</k1>
<k1>Restriction Mapping</k1>
<k1>Virion/genetics</k1>
<ab>The adeno-associated virus (AAV) genome is a linear, single polynucleotide chain with inverted terminal repeats of 145 bases. In order to test whether the terminal repeats at opposite ends of the genome have to be able to completely base-pair during DNA replication, we have created chimeric genomes in which an 11 base symmetrical sequence has been deleted from the terminal repeat at one end of the genome and replaced by a different 12 base symmetrical sequence. We have used these chimeric constructs either as a duplex insert in pBR322 or as purified duplex virion DNA to transfect adenovirus-infected HeLa cells. When chimeric duplex virion DNA was used, all of the progeny virions obtained after two cell passages contained DNA with wild-type sequences in both terminal repeats. When plasmid clones were used, the structure of virion DNA depended on the original orientation. If the mutant terminal repeat was originally at the right end of the genome (terminus of genetic map), all progeny terminal repeat sequences were again wild-type. However, if the original construct contained the mutant sequence in the left terminal repeat, the majority of progeny molecules were parental in type (i.e. mutant left and wild-type right terminal repeat). We conclude (1) although the terminal repeats at opposite ends of the genome may interact during DNA replication, it is not necessary that they be perfectly complementary. (2) In direct competition, the wild-type sequence displays an advantage over the mutant allele. (3) In a plasmid clone, the terminal repeat on the left end of the genome is at an advantage in a competitive situation. We note that the left terminal repeat is adjacent to a transcriptional promoter.</ab>
<no>LR: 20071114; GR: AI-01770/AI/NIAID NIH HHS/United States; GR: AI-22251/AI/NIAID NIH HHS/United States; JID: 2985088R; 0 (DNA, Viral); ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<ad>Department of Immunology and Medical Microbiology, College of Medicine, University of Florida, Gainesville 32610.</ad>
<an>PMID: 2539485; 0022-2836(89)90526-3 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2539485</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1853</id>
<a1>Bohenzky,R. A.</a1>
<a1>LeFebvre,R. B.</a1>
<a1>Berns,K. I.</a1>
<t1>Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1988</yr>
<fd>Oct</fd>
<vo>166</vo>
<is>2</is>
<sp>316</sp>
<op>327</op>
<k1>Cloning, Molecular</k1>
<k1>DNA Mutational Analysis</k1>
<k1>DNA Repair</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Hydrogen Bonding</k1>
<k1>Kinetics</k1>
<k1>Molecular Structure</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<ab>The defective parvovirus, adeno-associated virus (AAV), contains a single-stranded DNA genome of 4681 bases with inverted terminal repeats of 145 bases. The distal 125 bases of the repeat are palindromic allowing a hairpin to form for initiation of DNA synthesis. The palindromic region contains three palindromes, two smaller internal palindromes flanked by a larger palindrome, which allow the hairpinned DNA to assume a T-shaped conformation during DNA replication. Deletion of an internal palindrome forming one of the crossarms of the T results in the inability of the AAV genome to be rescued from plasmid sequences and replicated. Restoration of the crossarm sequences with DNA that differs in primary sequence but maintains the symmetry of the palindrome results in viable AAV and propagation of the mutant sequences. In this paper we report further studies on the nature of mutants made within the crossarm of the T. Two types of substitution mutants were analyzed. Symmetrical sequence substitution mutants were viable as previously reported. An analysis of the kinetics of AAV DNA accumulation showed that the symmetrical sequence substitution mutants were indistinguishable from wild-type AAV. This was true if the AAV DNA was introduced into the cells either as plasmid DNA or as DNA extracted from virions. In contrast, intermolecular competition experiments showed either a dominance of the wild-type sequence or codominance of both sequences when both alleles were cotransfected into helper virus-infected cells. A preference for the wild-type sequence may also exist but is not required for efficient AAV replication. The second type of mutation studied was an asymmetrical sequence substitution mutant. This mutant was replicated but at a level too low to be propagated. These data suggest that symmetry is required in the internal palindromic region, presumably for the formation of the crossarm structure in the T-shape.</ab>
<no>LR: 20071114; GR: AI-07110/AI/NIAID NIH HHS/United States; GR: AI-22251/AI/NIAID NIH HHS/United States; JID: 0110674; 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<ad>Department of Immunology and Medical Microbiology, College of Medicine, University of Florida, Gainesville 32610.</ad>
<an>PMID: 2845646</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2845646</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1796</id>
<a1>Brantly,M. L.</a1>
<a1>Spencer,L. T.</a1>
<a1>Humphries,M.</a1>
<a1>Conlon,T. J.</a1>
<a1>Spencer,C. T.</a1>
<a1>Poirier,A.</a1>
<a1>Garlington,W.</a1>
<a1>Baker,D.</a1>
<a1>Song,S.</a1>
<a1>Berns,K. I.</a1>
<a1>Muzyczka,N.</a1>
<a1>Snyder,R. O.</a1>
<a1>Byrne,B. J.</a1>
<a1>Flotte,T. R.</a1>
<t1>Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2006</yr>
<fd>Dec</fd>
<vo>17</vo>
<is>12</is>
<sp>1177</sp>
<op>1186</op>
<k1>Adult</k1>
<k1>Aged</k1>
<k1>DNA, Recombinant/blood</k1>
<k1>Dependovirus/classification/genetics/immunology</k1>
<k1>Female</k1>
<k1>Gene Therapy/adverse effects/methods</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Injections, Intramuscular</k1>
<k1>Lymphocyte Activation</k1>
<k1>Male</k1>
<k1>Middle Aged</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>alpha 1-Antitrypsin/blood/genetics</k1>
<k1>alpha 1-Antitrypsin Deficiency/genetics/immunology/therapy</k1>
<ab>A phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 (rAAV2) alpha1-antitrypsin (AAT) vector was performed in 12 AAT-deficient adults, 10 of whom were male. All subjects were either homozygous for the most common AAT mutation (a missense mutation designated PI*Z) or compound heterozygous for PI*Z and another mutation known to cause disease. There were four dose cohorts, ranging from 2.1 x 10(12) vector genomes (VG) to 6.9 x 10(13) VG, with three subjects per cohort. Subjects were injected sequentially in a dose-escalating fashion with a minimum of 14 days between patients. Subjects who had been receiving AAT protein replacement discontinued that therapy 28 days before vector administration. There were no vector-related serious adverse events in any of the 12 participants. Vector DNA sequences were detected in the blood between 1 and 3 days after injection in nearly all patients receiving doses of 6.9 x 10(12) VG or higher. Anti-AAV2 capsid antibodies were present and rose after vector injection, but no other immune responses were detected. One subject who had not been receiving protein replacement exhibited low-level expression of wild-type M-AAT in the serum (82 nM), which was detectable 30 days after receiving an injection of 2.1 x 10(13) VG. Unfortunately, residual but declining M-AAT levels from the washout of the protein replacement elevated background levels sufficiently to obscure any possible vector expression in that range in most of the other individuals in the higher dose cohorts.</ab>
<no>LR: 20071203; GR: DK58327/DK/NIDDK NIH HHS/United States; GR: HL4456/HL/NHLBI NIH HHS/United States; GR: HL69877/HL/NHLBI NIH HHS/United States; GR: RR00082/RR/NCRR NIH HHS/United States; JID: 9008950; 0 (DNA, Recombinant); 0 (alpha 1-Antitrypsin); ppublish</no>
<pp>United States</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>Department of Medicine, University of Florida, Gainesville, FL 32611, USA.</ad>
<an>PMID: 17115945</an>
<la>eng</la>
<sf>Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov&#39;t; IM</sf>
<do>10.1089/hum.2006.17.1177</do>
<ol>Unknown(0)</ol>
<pmid>17115945</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1883</id>
<a1>Carter,B. J.</a1>
<a1>Fife,K. H.</a1>
<a1>de la Maza,L. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Genome localization of adeno-associated virus RNA</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1976</yr>
<fd>Sep</fd>
<vo>19</vo>
<is>3</is>
<sp>1044</sp>
<op>1053</op>
<k1>DNA Restriction Enzymes/metabolism</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>Genes</k1>
<k1>Nucleic Acid Hybridization</k1>
<k1>RNA, Viral/biosynthesis</k1>
<k1>Satellite Viruses/metabolism</k1>
<k1>Transcription, Genetic</k1>
<ab>In previous work, linear duplex molecules of adeno-associated virus, type 2 (AAV2), DNA were cleaved with the restriction endonucleases R-EcoRI, R-HindII, and R-HindIII. The physical order of the specific fragments obtained was deduced and oriented with respect to the DNA strand polarity and the direction of transcription. Stable AAV RNA is transcribed only from 70% of the minus DNA strand. We report here RNA-DNA hybridization experiments using these restriction fragments to obtain a more accurate map of the portion of the AAV genome represented in stable RNA. The data obtained with several sets of restriction fragments annealed to either whole-cell RNA or poly(A)-containing RNA were internally consistent. The AAV RNA annealed with a continuous region of the AAV DNA, beginning at 0.18 map units (18%) from the left end of the molecule and ending at 0.88 map units. In addition, the restriction endonuclease BamHI was found to make one specific cleavage in AAV2 DNA at 0.22 map units, which is 0.04 map units (i.e., 160 nucleotides) to the right (&amp;quot;&amp;quot;down stream&amp;#39;&amp;#39;) of the point corresponding to the 5&amp;#39; end of the viral mRNA.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Viral); 0 (RNA, Viral); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC354945; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 972429</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>972429</pmid>
<pmcid>PMC354945</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1807</id>
<a1>Chen,S.</a1>
<a1>Agarwal,A.</a1>
<a1>Glushakova,O. Y.</a1>
<a1>Jorgensen,M. S.</a1>
<a1>Salgar,S. K.</a1>
<a1>Poirier,A.</a1>
<a1>Flotte,T. R.</a1>
<a1>Croker,B. P.</a1>
<a1>Madsen,K. M.</a1>
<a1>Atkinson,M. A.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Berns,K. I.</a1>
<a1>Tisher,C. C.</a1>
<t1>Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors</t1>
<jf>Journal of the American Society of Nephrology : JASN</jf>
<jo>J.Am.Soc.Nephrol.</jo>
<yr>2003</yr>
<fd>Apr</fd>
<vo>14</vo>
<is>4</is>
<sp>947</sp>
<op>958</op>
<k1>Animals</k1>
<k1>Dependovirus/genetics</k1>
<k1>Epithelial Cells/physiology</k1>
<k1>Gene Expression/genetics</k1>
<k1>Gene Therapy/methods</k1>
<k1>Genes, Reporter/genetics</k1>
<k1>Genetic Vectors/genetics</k1>
<k1>Green Fluorescent Proteins</k1>
<k1>Indicators and Reagents/administration &amp; dosage</k1>
<k1>Infusions, Intra-Arterial</k1>
<k1>Kidney/physiology</k1>
<k1>Kidney Tubules/physiology</k1>
<k1>Luminescent Proteins/administration &amp; dosage</k1>
<k1>Male</k1>
<k1>Rats</k1>
<k1>Rats, Inbred Lew</k1>
<k1>Renal Artery</k1>
<k1>Transgenes/genetics</k1>
<ab>Gene therapy has the potential to provide a therapeutic strategy for numerous renal diseases such as diabetic nephropathy, chronic rejection, Alport syndrome, polycystic kidney disease, and inherited tubular disorders. In previous studies using cationic liposomes or adenoviral or retroviral vectors to deliver genes into the kidney, transgene expression has been transient and often associated with adverse host immune responses, particularly with the use of adenoviral vectors. The unique properties of recombinant adeno-associated viral (rAAV) vectors permit long-term stable transgene expression with a relatively low host immune response. The purpose of the present study was to evaluate gene expression in the rat kidney after intrarenal arterial infusion of a rAAV (serotype 2) vector encoding green fluorescence protein (GFP) induced by a cytomegalovirus-chicken beta-actin hybrid promoter. The left kidney of experimental animals was treated with either saline or transduced with rAAV2-GFP (0.125 ml/100 g body wt, 1 x 10(10)/ml infectious units) through the renal artery. A time-dependent expression of GFP was observed in all kidneys injected with rAAV2-GFP, with maximal expression observed at 6 wk posttransduction. The expression of GFP was restricted to cells in the S(3) segment of the proximal tubule and intercalated cells in the collecting duct, the latter identified by co-localization with H(+)-ATPase. No transduction was observed in the glomeruli or the intrarenal vasculature. These studies demonstrate successful transgene expression in tubular epithelial cells, specifically in the S(3) segment of the proximal tubule and intercalated cells, after intrarenal administration of a rAAV vector and provide the impetus for further studies to exploit its use as a tool for gene therapy in the kidney.</ab>
<no>LR: 20071114; GR: DK58237/DK/NIDDK NIH HHS/United States; GR: RR16586/RR/NCRR NIH HHS/United States; JID: 9013836; 0 (Indicators and Reagents); 0 (Luminescent Proteins); 147336-22-9 (Green Fluorescent Proteins); ppublish</no>
<pp>United States</pp>
<sn>1046-6673; 1046-6673</sn>
<ad>Department of Medicine, University of Florida, Gainesville, Florida 32610, USA.</ad>
<an>PMID: 12660329</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>12660329</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1801</id>
<a1>Chen,S.</a1>
<a1>Kapturczak,M.</a1>
<a1>Loiler,S. A.</a1>
<a1>Zolotukhin,S.</a1>
<a1>Glushakova,O. Y.</a1>
<a1>Madsen,K. M.</a1>
<a1>Samulski,R. J.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Campbell-Thompson,M.</a1>
<a1>Berns,K. I.</a1>
<a1>Flotte,T. R.</a1>
<a1>Atkinson,M. A.</a1>
<a1>Tisher,C. C.</a1>
<a1>Agarwal,A.</a1>
<t1>Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2005</yr>
<fd>Feb</fd>
<vo>16</vo>
<is>2</is>
<sp>235</sp>
<op>247</op>
<k1>Animals</k1>
<k1>Aorta/metabolism</k1>
<k1>Capsid/metabolism</k1>
<k1>Cells, Cultured</k1>
<k1>DNA, Recombinant/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Endothelium, Vascular/chemistry/metabolism/virology</k1>
<k1>Genetic Vectors</k1>
<k1>Green Fluorescent Proteins/metabolism</k1>
<k1>Heparin/metabolism</k1>
<k1>Humans</k1>
<k1>Male</k1>
<k1>Myocytes, Smooth Muscle/chemistry/metabolism/virology</k1>
<k1>N-Acetylneuraminic Acid/metabolism</k1>
<k1>Neuraminidase/pharmacology</k1>
<k1>Rats</k1>
<k1>Rats, Inbred Lew</k1>
<k1>Transduction, Genetic</k1>
<k1>alpha 1-Antitrypsin/genetics</k1>
<k1>beta-Galactosidase/metabolism</k1>
<ab>Recombinant adeno-associated virus (rAAV) has become an attractive tool for gene therapy because of its ability to transduce both dividing and nondividing cells, elicit a limited immune response, and the capacity for imparting long-term transgene expression. Previous studies have utilized rAAV serotype 2 predominantly and found that transduction of vascular cells is relatively inefficient. The purpose of the present study was to evaluate the transduction efficiency of rAAV serotypes 1 through 5 in human and rat aortic endothelial cells (HAEC and RAEC). rAAV vectors with AAV2 inverted terminal repeats containing the human alpha1-antitrypsin (hAAT) gene were transcapsidated using helper plasmids to provide viral capsids for the AAV1 through 5 serotypes. True type rAAV2 and 5 vectors encoding beta-galactosidase or green fluorescence protein were also studied. Infection with rAAV1 resulted in the most efficient transduction in both HAEC and RAEC compared to other serotypes (p &amp;lt; 0.001) at 7 days posttransduction. Interestingly, expression was increased in cells transduced with rAAV5 to levels surpassing rAAV1 by day 14 and 21. Transduction with rAAV1 was completely inhibited by removal of sialic acid with sialidase, while heparin had no effect. These studies are the first demonstration that sialic acid residues are required for rAAV1 transduction in endothelial cells. Transduction of rat aortic segments ex vivo and in vivo demonstrated significant transgene expression in endothelial and smooth muscle cells with rAAV1 and 5 serotype vectors, in comparison to rAAV2. These results suggest the unique potential of rAAV1 and rAAV5-based vectors for vascular-targeted gene-based therapeutic strategies.</ab>
<no>LR: 20091118; GR: P01 GM059299-050003/GM/NIGMS NIH HHS/United States; GR: P01 HL051818-12/HL/NHLBI NIH HHS/United States; GR: P01 HL066973/HL/NHLBI NIH HHS/United States; GR: P01 HL066973-05/HL/NHLBI NIH HHS/United States; GR: R21 DK067472/DK/NIDDK NIH HHS/United States; JID: 9008950; 0 (DNA, Recombinant); 0 (alpha 1-Antitrypsin); 131-48-6 (N-Acetylneuraminic Acid); 147336-22-9 (Green Fluorescent Proteins); 9005-49-6 (Heparin); EC 3.2.1.18 (Neuraminidase); EC 3.2.1.23 (beta-Galactosidase); NIHMS7858; OID: NLM: NIHMS7858; OID: NLM: PMC1364465; ppublish</no>
<pp>United States</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</ad>
<an>PMID: 15761263</an>
<la>eng</la>
<sf>Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1089/hum.2005.16.235</do>
<ol>Unknown(0)</ol>
<pmid>15761263</pmid>
<pmcid>PMC1364465</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1799</id>
<a1>Chen,S.</a1>
<a1>Kapturczak,M. H.</a1>
<a1>Wasserfall,C.</a1>
<a1>Glushakova,O. Y.</a1>
<a1>Campbell-Thompson,M.</a1>
<a1>Deshane,J. S.</a1>
<a1>Joseph,R.</a1>
<a1>Cruz,P. E.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Madsen,K. M.</a1>
<a1>Croker,B. P.</a1>
<a1>Berns,K. I.</a1>
<a1>Atkinson,M. A.</a1>
<a1>Flotte,T. R.</a1>
<a1>Tisher,C. C.</a1>
<a1>Agarwal,A.</a1>
<t1>Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>2005</yr>
<fd>May 17</fd>
<vo>102</vo>
<is>20</is>
<sp>7251</sp>
<op>7256</op>
<k1>Analysis of Variance</k1>
<k1>Animals</k1>
<k1>Aorta/transplantation</k1>
<k1>Blotting, Western</k1>
<k1>Cell Proliferation</k1>
<k1>Dependovirus</k1>
<k1>Endothelial Cells/cytology</k1>
<k1>Enzyme-Linked Immunosorbent Assay</k1>
<k1>Genetic Vectors</k1>
<k1>Graft Rejection/metabolism/prevention &amp; control</k1>
<k1>Heat-Shock Proteins/metabolism</k1>
<k1>Heme Oxygenase (Decyclizing)</k1>
<k1>Inflammation/metabolism/prevention &amp; control</k1>
<k1>Interleukin-10/blood/genetics/metabolism</k1>
<k1>Oxygenases/metabolism</k1>
<k1>Rats</k1>
<k1>Transgenes/genetics</k1>
<k1>Transplantation, Homologous</k1>
<ab>Interleukin 10 (IL-10) is a pleiotropic cytokine with well known antiinflammatory, immunosuppressive, and immunostimulatory properties. Chronic allograft rejection, characterized by vascular neointimal proliferation, is a major cause of organ transplant loss, particularly in heart and kidney transplant recipients. In a Dark Agouti to Lewis rat model of aortic transplantation, we evaluated the effects of a single intramuscular injection of a recombinant adeno-associated viral vector (serotype 1) encoding IL-10 (rAAV1-IL-10) on neointimal proliferation and inflammation. rAAV1-IL-10 treatment resulted in a significant reduction of neointimal proliferation and graft infiltration with macrophages and T and B lymphocytes. The mechanism underlying the protective effects of IL-10 in aortic allografts involved heme oxygenase 1 (HO-1) because inhibition of HO activity reversed not only neointimal proliferation but also inflammatory cell infiltration. Our results indicate that IL-10 attenuates neointimal proliferation and inflammatory infiltration and strongly imply that HO-1 is an important intermediary through which IL-10 regulates the inflammatory responses associated with chronic vascular rejection.</ab>
<no>LR: 20091118; JID: 7505876; 0 (Heat-Shock Proteins); 130068-27-8 (Interleukin-10); EC 1.13.- (Oxygenases); EC 1.14.99.3 (Heme Oxygenase (Decyclizing)); EC 1.14.99.3 (Hmox1 protein, rat); OID: NLM: PMC1090475; 2005/05/06 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Medicine, Nephrology Research and Training Center, University of Alabama at Birmingham, Birmingham, AL 35294.</ad>
<an>PMID: 15878989; 0502407102 [pii]</an>
<la>eng</la>
<sf>Comparative Study; Journal Article; Research Support, Non-U.S. Gov&#39;t; IM</sf>
<do>10.1073/pnas.0502407102</do>
<wp>20050506</wp>
<ol>Unknown(0)</ol>
<pmid>15878989</pmid>
<pmcid>PMC1090475</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1876</id>
<a1>Cheung,A. K.</a1>
<a1>Hoggan,M. D.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Berns,K. I.</a1>
<t1>Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1980</yr>
<fd>Feb</fd>
<vo>33</vo>
<is>2</is>
<sp>739</sp>
<op>748</op>
<k1>Base Sequence</k1>
<k1>Bone Marrow</k1>
<k1>Cell Line</k1>
<k1>Cell Transformation, Viral</k1>
<k1>DNA/metabolism</k1>
<k1>DNA Restriction Enzymes</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Humans</k1>
<k1>Plasmids</k1>
<k1>Recombination, Genetic</k1>
<ab>A clone of human cells (Detroit 6) latently infected by adeno-associated virus (AAV) has been characterized with regard to the status of the viral DNA. In both early (9 to 10) and late (118) passages of the clone, AAV-DNA was recombined with host DNA, at least in some cases as a head-to-tail tandem repeat, via the terminal sequences of the viral genome. However, it was not possible to distinguish between integration into chromosomal DNA and very large plasmids (&amp;lt; 20 x 10(6) molecular weight) which contain both viral and cellular DNA sequences. Although evidence for some modifications of the viral sequence was obtained, most of the integrated sequences appeared to be intact. In some cases sequences of undetermined origin separated adjacent copies of the viral genome. Free copies of the AAV genome were detectable in late passage cells, but not in early passage cells. The orientation of nucleotide sequences present in the free AAV DNA from late passage cells was indistinguishable from that of virion DNA. With the notable exception, the organization of the integrated AAV sequences as determined by restriction enzyme digestion remained constant with continued passage. Digestion with SmaI, which cleaves within the palindromic region of the terminal repetition in AAV DNA, produced reproducibly different patterns when early and late passage DNAs were compared. Several models for rescue of free copies of the genome from the integrated DNA are possible, all of which involve the terminal repetition.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Viral); 9007-49-2 (DNA); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC288599; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 6251245</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6251245</pmid>
<pmcid>PMC288599</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1793</id>
<a1>Daya,S.</a1>
<a1>Berns,K. I.</a1>
<t1>Gene therapy using adeno-associated virus vectors</t1>
<jf>Clinical microbiology reviews</jf>
<jo>Clin.Microbiol.Rev.</jo>
<yr>2008</yr>
<fd>Oct</fd>
<vo>21</vo>
<is>4</is>
<sp>583</sp>
<op>593</op>
<k1>Animals</k1>
<k1>Dependovirus/genetics/pathogenicity</k1>
<k1>Gene Therapy/adverse effects/methods</k1>
<k1>Humans</k1>
<k1>Transduction, Genetic</k1>
<ab>SUMMARY: The unique life cycle of adeno-associated virus (AAV) and its ability to infect both nondividing and dividing cells with persistent expression have made it an attractive vector. An additional attractive feature of the wild-type virus is the lack of apparent pathogenicity. Gene transfer studies using AAV have shown significant progress at the level of animal models; clinical trials have been noteworthy with respect to the safety of AAV vectors. No proven efficacy has been observed, although in some instances, there have been promising observations. In this review, topics in AAV biology are supplemented with a section on AAV clinical trials with emphasis on the need for a deeper understanding of AAV biology and the development of efficient AAV vectors. In addition, several novel approaches and recent findings that promise to expand AAV&amp;#39;s utility are discussed, especially in the context of combining gene therapy ex vivo with new advances in stem or progenitor cell biology.</ab>
<no>LR: 20091118; GR: DK58327/DK/NIDDK NIH HHS/United States; JID: 8807282; RF: 80; OID: NLM: PMC2570152; ppublish</no>
<pp>United States</pp>
<sn>1098-6618; 0893-8512</sn>
<ad>Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida 32610-3610, USA.</ad>
<an>PMID: 18854481; 21/4/583 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, N.I.H., Extramural; Review; IM</sf>
<do>10.1128/CMR.00008-08</do>
<ol>Unknown(0)</ol>
<pmid>18854481</pmid>
<pmcid>PMC2570152</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1792</id>
<a1>Daya,S.</a1>
<a1>Cortez,N.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>2009</yr>
<fd>Nov</fd>
<vo>83</vo>
<is>22</is>
<sp>11655</sp>
<op>11664</op>
<k1>Blotting, Southern</k1>
<k1>Cell Line</k1>
<k1>DNA Ligases/metabolism</k1>
<k1>DNA, Recombinant/genetics</k1>
<k1>DNA-Activated Protein Kinase/metabolism</k1>
<k1>Dependovirus/physiology</k1>
<k1>Genetic Vectors/genetics</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>Virus Integration/physiology</k1>
<ab>Adeno-associated virus type 2 (AAV 2) is the only eukaryotic virus capable of site-specific integration; the target site is at chromosome 19q13.4, a site termed AAVS1. The biology of AAV latency has been extensively studied in cell culture, yet the precise mechanism and the required cellular factors are not known. In this study, we assessed the relative frequencies of stable site-specific integration by characterization of cell clones containing integrated AAV vectors. By this assay, two proteins involved in nonhomologous end joining (NHEJ), DNAPKcs and ligase IV, exhibit differential effects on AAV site-specific integration. DNAPKcs is not required; its presence increases the frequency of junction formation indicative of site-specific integration, but seems to reduce the ratio of site-specific integration to random integration (i.e., the latter is even more enhanced). In contrast, site-specific integration is significantly reduced relative to random integration in cells deficient in ligase IV expression. Furthermore, we show that single-stranded AAV vectors are better substrates for site-specific integration than are self-complementary AAV vectors; the absence of DNAPKcs did not affect the targeted integration of these double-stranded AAV vectors. Together, these data suggest that NHEJ proteins participate in site-specific integration, and indicate a role for the single-stranded form of AAV DNA in targeted integration.</ab>
<no>LR: 20100504; GR: P01 DK58327/DK/NIDDK NIH HHS/United States; JID: 0113724; 0 (DNA, Recombinant); EC 2.7.11.1 (DNA-Activated Protein Kinase); EC 6.5.1.- (DNA Ligases); EC 6.5.1.1 (DNA ligase (ATP)); OID: NLM: PMC2772704; 2009/09/16 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>1098-5514; 0022-538X</sn>
<ad>Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida 32608, USA.</ad>
<an>PMID: 19759155; JVI.01040-09 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, N.I.H., Extramural; IM</sf>
<do>10.1128/JVI.01040-09</do>
<wp>20090916</wp>
<ol>Unknown(0)</ol>
<pmid>19759155</pmid>
<pmcid>PMC2772704</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1798</id>
<a1>Deng,W. T.</a1>
<a1>Yan,Z.</a1>
<a1>Dinculescu,A.</a1>
<a1>Pang,J.</a1>
<a1>Teusner,J. T.</a1>
<a1>Cortez,N. G.</a1>
<a1>Berns,K. I.</a1>
<a1>Hauswirth,W. W.</a1>
<t1>Adeno-associated virus-mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2005</yr>
<fd>Nov</fd>
<vo>16</vo>
<is>11</is>
<sp>1247</sp>
<op>1254</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>Blotting, Western</k1>
<k1>DNA Primers</k1>
<k1>Dependovirus/genetics</k1>
<k1>Disease Models, Animal</k1>
<k1>Exons</k1>
<k1>Gene Therapy</k1>
<k1>Genetic Vectors</k1>
<k1>Mice</k1>
<k1>Mice, Inbred CBA</k1>
<k1>Oxygen/administration &amp; dosage/adverse effects</k1>
<k1>Retinal Diseases/drug therapy/etiology</k1>
<k1>Retinal Neovascularization/prevention &amp; control</k1>
<k1>Reverse Transcriptase Polymerase Chain Reaction</k1>
<k1>Vascular Endothelial Growth Factor A/genetics/secretion/therapeutic use</k1>
<ab>Vascular endothelial growth factor (VEGF) has been demonstrated to be a key stimulator of retinal neovascularization (NV), the most common cause of severe and progressive vision loss. In this study, we used a mouse model of oxygen-induced retinopathy (OIR) to explore the potential of gene expression and secretion of short VEGF peptides as a treatment. Peptide-encoding fragments of exons 6 and 7 of the VEGF gene were cloned into a recombinant adeno-associated virus (rAAV) vector. Expression of each peptide in vector-injected eyes was confirmed by reverse transcription-polymerase chain reaction and Western blot analysis. Intravitreal injection of each rAAV vector inhibited retinal NV by 71-83% (p &amp;lt; 0.001) compared with contralateral control eyes in the OIR mouse. Injection and expression of these peptides did not seem to affect the normal appearance of the retina. The results demonstrated that exon 6- and 7-derived VEGF peptides effectively inhibited oxygen-induced retinal NV. Therefore, these VEGF peptides have potential in the treatment of angiogenesis-associated retinal diseases in humans.</ab>
<no>LR: 20060421; JID: 9008950; 0 (DNA Primers); 0 (Vascular Endothelial Growth Factor A); 7782-44-7 (Oxygen); ppublish</no>
<pp>United States</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>Department of Ophthalmology and Powell Gene Therapy Center, University of Florida, College of Medicine, Gainesville, FL 32610, USA. wdeng@ufl.edu</ad>
<an>PMID: 16259558</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<do>10.1089/hum.2005.16.1247</do>
<ol>Unknown(0)</ol>
<pmid>16259558</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1803</id>
<a1>Dutheil,N.</a1>
<a1>Yoon-Robarts,M.</a1>
<a1>Ward,P.</a1>
<a1>Henckaerts,E.</a1>
<a1>Skrabanek,L.</a1>
<a1>Berns,K. I.</a1>
<a1>Campagne,F.</a1>
<a1>Linden,R. M.</a1>
<t1>Characterization of the mouse adeno-associated virus AAVS1 ortholog</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>2004</yr>
<fd>Aug</fd>
<vo>78</vo>
<is>16</is>
<sp>8917</sp>
<op>8921</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Chromosomes, Human, Pair 19/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Mice</k1>
<k1>Molecular Sequence Data</k1>
<k1>NIH 3T3 Cells</k1>
<k1>Proteins/genetics/metabolism</k1>
<k1>Sequence Alignment</k1>
<k1>Virus Integration</k1>
<ab>The nonpathogenic human adeno-associated virus (AAV) has developed a mechanism to integrate its genome into human chromosome 19 at 19q13.4 (termed AAVS1), thereby establishing latency. Here, we provide evidence that the chromosomal signals required for site-specific integration are conserved in the mouse genome proximal to the recently identified Mbs85 gene. These sequence motifs can be specifically nicked by the viral Rep protein required for the initiation of site-specific AAV DNA integration. Furthermore, these signals can serve as a minimal origin for Rep-dependent DNA replication. In addition, we isolated the mouse Mbs85 proximal promoter and show transcriptional activity in three mouse cell lines.</ab>
<no>LR: 20091118; GR: DK50795/DK/NIDDK NIH HHS/United States; GR: GM62234/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (Proteins); OID: NLM: PMC479059; ppublish</no>
<pp>United States</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Carl C. Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Pl., Box 1496, New York, NY 10029, USA.</ad>
<an>PMID: 15280500; 78/16/8917 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1128/JVI.78.16.8917-8921.2004</do>
<ol>Unknown(0)</ol>
<pmid>15280500</pmid>
<pmcid>PMC479059</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1823</id>
<a1>Dyall,J.</a1>
<a1>Berns,K. I.</a1>
<t1>Site-specific integration of adeno-associated virus into an episome with the target locus via a deletion-substitution mechanism</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1998</yr>
<fd>Jul</fd>
<vo>72</vo>
<is>7</is>
<sp>6195</sp>
<op>6198</op>
<k1>Dependovirus/genetics</k1>
<k1>Plasmids</k1>
<k1>Recombination, Genetic</k1>
<k1>Virus Integration</k1>
<ab>Five site-specific adeno-associated virus integrants generated in a model system with an Epstein-Barr virus- based shuttle vector have been characterized. The results suggest a deletion-substitution mechanism of recombination.</ab>
<no>LR: 20091118; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0113724; OID: NLM: PMC110435; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Microbiology, W. R. Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA.</ad>
<an>PMID: 9621089</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>9621089</pmid>
<pmcid>PMC110435</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1819</id>
<a1>Dyall,J.</a1>
<a1>Szabo,P.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus (AAV) site-specific integration: formation of AAV-AAVS1 junctions in an in vitro system</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1999</yr>
<fd>Oct 26</fd>
<vo>96</vo>
<is>22</is>
<sp>12849</sp>
<op>12854</op>
<k1>Base Sequence</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA Primers</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genes, Viral</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>Recombination, Genetic</k1>
<k1>Virus Integration</k1>
<ab>An in vitro system to study the mechanism of site-specific integration of adeno-associated virus (AAV) was developed. This system is based on two substrates, a linear or circular AAV donor and a circular acceptor containing the preintegration locus AAVS1. In the presence of HeLa extract and the His-Tag-purified Rep68 protein, specific covalent junctions between AAV and AAVS1 were formed and detected by PCR. The majority of the junctions were located within the Rep binding site of both the AAV and the AAVS1 substrates, underlining the involvement of the Rep protein. A limited amount of replication and the presence of nuclear factors promoted the efficiency of the reaction. The process was ATP-dependent, indicating that the helicase activity of Rep may be important in the formation of the junctions. According to current models of integration, the formation of the junctions would represent a first step in the process of AAV integration. This step could be crucial for the site specificity of the recombination event that leads to the integration of AAV into human chromosome 19 in vivo.</ab>
<no>LR: 20091118; GR: AI 22251/AI/NIAID NIH HHS/United States; GR: GM 50032/GM/NIGMS NIH HHS/United States; JID: 7505876; 0 (DNA Primers); OID: NLM: PMC23128; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.</ad>
<an>PMID: 10536011</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>10536011</pmid>
<pmcid>PMC23128</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1834</id>
<a1>Einerhand,M. P.</a1>
<a1>Antoniou,M.</a1>
<a1>Zolotukhin,S.</a1>
<a1>Muzyczka,N.</a1>
<a1>Berns,K. I.</a1>
<a1>Grosveld,F.</a1>
<a1>Valerio,D.</a1>
<t1>Regulated high-level human beta-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer</t1>
<jf>Gene therapy</jf>
<jo>Gene Ther.</jo>
<yr>1995</yr>
<fd>Jul</fd>
<vo>2</vo>
<is>5</is>
<sp>336</sp>
<op>343</op>
<k1>Animals</k1>
<k1>Cell Line, Transformed</k1>
<k1>Clone Cells</k1>
<k1>Cloning, Molecular</k1>
<k1>Dependovirus/genetics</k1>
<k1>Erythroid Precursor Cells/metabolism</k1>
<k1>Gene Expression Regulation, Viral</k1>
<k1>Gene Transfer Techniques</k1>
<k1>Globins/genetics</k1>
<k1>Humans</k1>
<k1>Leukemia, Erythroblastic, Acute/genetics/pathology</k1>
<k1>Mice</k1>
<k1>Recombination, Genetic</k1>
<k1>Transduction, Genetic</k1>
<ab>Gene therapy approaches for beta-thalassemia and sickle cell anemia focus on the transfer of a human beta-globin gene into the patient&amp;#39;s hematopoietic stem cells (HSC). Expression of the transferred sequences should be erythroid specific and match the expression of the endogenous alpha-globin genes in adult erythropoiesis. Here we explore the potential of recombinant adeno-associated virus (AAV) vectors for human beta-globin gene transfer. We have constructed a recombinant AAV-vector containing a human beta-globin gene together with the DNasel hypersensitive sites 4, 3 and 2 of the human beta-globin locus control region. The vector replicates to high titers and can efficiently transduce hematopoietic and non-hematopoietic cells. In transduced and G418 selected murine erythroleukemia (MEL) cell clones, human beta-globin gene expression was regulated and reached levels comparable to endogenous murine beta maj. These data show that AAV-vectors are promising tools in gene therapy approaches for the haemoglobinopathies.</ab>
<no>LR: 20081121; GR: R01HL/DK50257/HL/NHLBI NIH HHS/United States; JID: 9421525; 9004-22-2 (Globins); ppublish</no>
<pp>ENGLAND</pp>
<sn>0969-7128; 0969-7128</sn>
<ad>Department of Medical Biochemistry, University of Leiden, Rijswijk, The Netherlands.</ad>
<an>PMID: 7671109</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>7671109</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1882</id>
<a1>Fife,K. H.</a1>
<a1>Berns,K. I.</a1>
<a1>Murray,K.</a1>
<t1>Structure and nucleotide sequence of the terminal regions of adeno-associated virus DNA</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1977</yr>
<fd>May 15</fd>
<vo>78</vo>
<is>2</is>
<sp>475</sp>
<op>477</op>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>DNA Restriction Enzymes/metabolism</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Deoxyribonucleases/metabolism</k1>
<k1>Nucleic Acid Denaturation</k1>
<k1>Nucleotides/analysis</k1>
<k1>Oligonucleotides/analysis</k1>
<k1>Phosphoric Diester Hydrolases/metabolism</k1>
<k1>Satellite Viruses/analysis</k1>
<no>LR: 20061115; JID: 0110674; 0 (DNA, Viral); 0 (Nucleotides); 0 (Oligonucleotides); EC 3.1.- (Deoxyribonucleases); EC 3.1.21.- (DNA Restriction Enzymes); EC 3.1.4.- (Phosphoric Diester Hydrolases); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 194395</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>194395</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1800</id>
<a1>Flotte,T. R.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus: a ubiquitous commensal of mammals</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2005</yr>
<fd>Apr</fd>
<vo>16</vo>
<is>4</is>
<sp>401</sp>
<op>407</op>
<k1>Animals</k1>
<k1>Capsid/chemistry</k1>
<k1>Dependovirus/classification/pathogenicity/physiology</k1>
<k1>Genome, Viral</k1>
<k1>Humans</k1>
<k1>Parvoviridae Infections/epidemiology/etiology/virology</k1>
<k1>Virion/chemistry</k1>
<no>LR: 20071114; GR: DK58327/DK/NIDDK NIH HHS/United States; GR: EY13729/EY/NEI NIH HHS/United States; GR: HL51811/HL/NHLBI NIH HHS/United States; GR: HL59412/HL/NHLBI NIH HHS/United States; GR: HL69877/HL/NHLBI NIH HHS/United States; GR: RR00082/RR/NCRR NIH HHS/United States; GR: RR16586/RR/NCRR NIH HHS/United States; JID: 9008950; RF: 82; ppublish</no>
<pp>United States</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>Department of Pediatrics, and Genetics Institute, University of Florida, Gainesville, FL 32610, USA. flotttr@peds.ufl.edu</ad>
<an>PMID: 15871671</an>
<la>eng</la>
<sf>Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<do>10.1089/hum.2005.16.401</do>
<ol>Unknown(0)</ol>
<pmid>15871671</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1889</id>
<a1>Gerry,H. W.</a1>
<a1>Kelly,T. J.,Jr</a1>
<a1>Berns,K. I.</a1>
<t1>Arrangement of nucleotide sequences in adeno-associated virus DNA</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1973</yr>
<fd>Sep 15</fd>
<vo>79</vo>
<is>2</is>
<sp>207</sp>
<op>225</op>
<k1>Adenoviridae/analysis</k1>
<k1>Base Sequence</k1>
<k1>Carbon Radioisotopes</k1>
<k1>Carcinoma</k1>
<k1>Cell Line</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>DNA, Circular/analysis</k1>
<k1>DNA, Single-Stranded/analysis/isolation &amp; purification</k1>
<k1>DNA, Viral/analysis/isolation &amp; purification</k1>
<k1>Escherichia coli/enzymology</k1>
<k1>Exonucleases</k1>
<k1>Humans</k1>
<k1>Microscopy, Electron</k1>
<k1>Molecular Weight</k1>
<k1>Mouth Neoplasms</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Nucleic Acid Denaturation</k1>
<k1>Nucleic Acid Renaturation</k1>
<k1>Phosphorus Radioisotopes</k1>
<k1>Satellite Viruses/analysis</k1>
<k1>Spectrophotometry, Ultraviolet</k1>
<k1>Thymidine</k1>
<k1>Tritium</k1>
<no>LR: 20041117; JID: 2985088R; 0 (Carbon Radioisotopes); 0 (DNA, Circular); 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (Phosphorus Radioisotopes); 10028-17-8 (Tritium); 50-89-5 (Thymidine); EC 3.1.- (Exonucleases); ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 4586409</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>4586409</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1886</id>
<a1>Geshelin,P.</a1>
<a1>Berns,K. I.</a1>
<t1>Characterization and localization of the naturally occurring cross-links in vaccinia virus DNA</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1974</yr>
<fd>Oct 5</fd>
<vo>88</vo>
<is>4</is>
<sp>785</sp>
<op>796</op>
<k1>Binding Sites</k1>
<k1>Carbon Radioisotopes</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>Chromatography, Ion Exchange</k1>
<k1>DNA, Single-Stranded/isolation &amp; purification</k1>
<k1>DNA, Viral/analysis/biosynthesis</k1>
<k1>Deoxyribonucleases</k1>
<k1>Endonucleases</k1>
<k1>Genes</k1>
<k1>Hela Cells</k1>
<k1>Hydroxyapatites</k1>
<k1>Kinetics</k1>
<k1>Microscopy, Electron</k1>
<k1>Molecular Weight</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Nucleic Acid Denaturation</k1>
<k1>Nucleic Acid Renaturation</k1>
<k1>Solubility</k1>
<k1>Thymidine/metabolism</k1>
<k1>Time Factors</k1>
<k1>Tritium</k1>
<k1>Vaccinia virus/analysis/metabolism</k1>
<no>LR: 20091027; JID: 2985088R; 0 (Carbon Radioisotopes); 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (Hydroxyapatites); 10028-17-8 (Tritium); 50-89-5 (Thymidine); EC 3.1.- (Deoxyribonucleases); EC 3.1.- (Endonucleases); ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 4427382</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>4427382</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1833</id>
<a1>Giraud,C.</a1>
<a1>Winocour,E.</a1>
<a1>Berns,K. I.</a1>
<t1>Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1995</yr>
<fd>Nov</fd>
<vo>69</vo>
<is>11</is>
<sp>6917</sp>
<op>6924</op>
<k1>Adenoviruses, Human/genetics/physiology</k1>
<k1>Base Sequence</k1>
<k1>Binding Sites</k1>
<k1>Cell Line</k1>
<k1>Chromosome Mapping</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genetic Vectors</k1>
<k1>Genome, Viral</k1>
<k1>Herpesvirus 4, Human/genetics</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Oligonucleotide Probes</k1>
<k1>Plasmids</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Recombination, Genetic</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Virus Integration</k1>
<ab>A model system using an episomal Epstein-Barr virus shuttle vector was recently developed to study the adeno-associated virus (AAV) site-specific integration event in chromosome 19q13.3-qter (C. Giraud, E. Winocour, and K.I. Berns, Proc. Natl. Acad. Sci. USA 91:10039-10043, 1994). In this study, we analyze the recombinant junctions generated after integration of the AAV genome into an Epstein-Barr virus shuttle vector carrying 8.2, 1.6, or 0.51 kb of the chromosome 19 preintegration sequence (AAVS1 locus). In most of the recombinants, one end of the viral genome was joined to a portion of the AAVS1 DNA previously shown to be a minimum target for AAV integration. Within this AAVS1 segment, the AAV insertion points were strikingly clustered around a binding site for the AAV regulatory protein. In all cases, the second junction with AAV occurred with vector DNA outside of the AAVS1 segment. With respect to the viral genome, one junction with the shuttle vector DNA occurred either within the AAV inverted terminal repeat (itr), or near the P5 promoter, approximately 100 nucleotides distal to a modified itr. The modified itr in 5 of 11 recombinants involved a head-to-tail organization. In one such instance, the AAV insert contained slightly more than one genome equivalent arranged in a head-to-tail manner with a junction close to the P5 promoter; the AAV insert in this recombinant episome could be rescued by adenovirus infection and replicated to virus particles. The significance of the head-to-tail organization is discussed in terms of the possible circularization of AAV DNA before or during integration.</ab>
<no>LR: 20091118; GR: AI122251/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (DNA-Binding Proteins); 0 (Oligonucleotide Probes); OID: NLM: PMC189609; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA.</ad>
<an>PMID: 7474109</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>7474109</pmid>
<pmcid>PMC189609</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1837</id>
<a1>Giraud,C.</a1>
<a1>Winocour,E.</a1>
<a1>Berns,K. I.</a1>
<t1>Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1994</yr>
<fd>Oct 11</fd>
<vo>91</vo>
<is>21</is>
<sp>10039</sp>
<op>10043</op>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA/genetics/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Embryo, Mammalian</k1>
<k1>Escherichia coli</k1>
<k1>Genetic Vectors</k1>
<k1>Herpesvirus 4, Human/genetics</k1>
<k1>Humans</k1>
<k1>Kidney</k1>
<k1>Molecular Sequence Data</k1>
<k1>Restriction Mapping</k1>
<k1>Virus Integration</k1>
<ab>Different regions of an 8.2-kb cloned DNA segment containing the target for adeno-associated virus (AAV) integration in human chromosome 19q13-3-qter (AAVS1 locus) were subcloned in an Epstein-Barr virus-based shuttle vector and propagated as episomes in a derivative of the 293 human embryonic kidney cell line. Preferential recombination with an infecting AAV genome was assessed by measuring the frequency of recombinants among the shuttle vectors recovered in Escherichia coli. The signals which direct recombination with the AAV genome were localized to a 510-nt region at the 5&amp;#39; end of the 8.2-kb AAVS1 DNA. Hence, the results indicate that site-specific integration of AAV is directed by a specific DNA sequence on human chromosome 19. An unusual degree of DNA heterogeneity in the recovered vector was also associated with the 510 nt at the 5&amp;#39; end of AAVS1 DNA, suggesting that the AAV chromosomal integration locus may be involved in genomic instability.</ab>
<no>LR: 20091118; GR: AI22251/AI/NIAID NIH HHS/United States; JID: 7505876; 9007-49-2 (DNA); OID: NLM: PMC44953; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 7937833</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>7937833</pmid>
<pmcid>PMC44953</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1859</id>
<a1>Grossman,Z.</a1>
<a1>Berns,K. I.</a1>
<a1>Winocour,E.</a1>
<t1>Structure of simian virus 40-adeno-associated virus recombinant genomes</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1985</yr>
<fd>Nov</fd>
<vo>56</vo>
<is>2</is>
<sp>457</sp>
<op>465</op>
<k1>Base Sequence</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA Restriction Enzymes/diagnostic use</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Recombination, Genetic</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Simian virus 40/genetics</k1>
<k1>Transfection</k1>
<ab>The structures of recombinant genomes formed by recombination between simian virus 40 (SV40) and adeno-associated virus 2 (AAV) DNAs after either DNA cotransfection or coinfection by virions were characterized. Two types of structures were found. Group A structures, found after cotransfection and in one of seven recombinants arising from coinfection, represented a simple deletion of SV40 sequences replaced by a slightly shorter AAV sequence. Group B structures were found in six of seven recombinants arising after virion coinfection. All contained either the left or right terminal sequences (approximately 250 to 450 bases) of the AAV genome adjacent to the SV40 origin of DNA replication. Only 350 to 650 bases (including the origin) remained of the SV40 sequence. The joined SV40-AAV sequences were present in the recombinant genome as a tandem repeat of a size that can be packaged into SV40 capsids.</ab>
<no>LR: 20091118; GENBANK/M12405; GR: AI 22251/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC252600; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 2997468</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2997468</pmid>
<pmcid>PMC252600</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1864</id>
<a1>Grossman,Z.</a1>
<a1>Winocour,E.</a1>
<a1>Berns,K. I.</a1>
<t1>Recombination between simian virus 40 and adeno-associated virus: virion coinfection compared to DNA cotransfection</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1984</yr>
<fd>Apr 15</fd>
<vo>134</vo>
<is>1</is>
<sp>125</sp>
<op>137</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Cercopithecus aethiops</k1>
<k1>Clone Cells/microbiology</k1>
<k1>DNA Replication</k1>
<k1>DNA Restriction Enzymes</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Recombination, Genetic</k1>
<k1>Simian virus 40/genetics/physiology</k1>
<k1>Time Factors</k1>
<k1>Transfection</k1>
<k1>Virion/physiology</k1>
<k1>Virus Replication</k1>
<ab>Recombination between simian virus 40 (SV40) and adeno-associated virus (AAV) has been detected, by infectious center in situ plaque hybridization procedures, after both DNA contransfection and virion coinfection of monkey BSC-1 cells. The number of cells producing recombinants (1 in a 1000) was the same irrespective of the way in which the SV40 and AAV genomes were delivered to the cell, despite the fact that 5-10 times more cells were infected after virion coinfection. Several other dosage-response parameters of the recombination process consequent to virion coinfection were comparable to those after DNA cotransfection. The sole difference observed between the two infection systems was that the SV40/AAV recombinants formed after virion coinfection contained an inordinately high proportion of AAV terminal DNA sequences. By separating the SV40 and AAV infections in time, such that the AAV infection was delayed until after certain events in the SV40 cycle had taken place, an optimum phase for recombination in the SV40 cycle was identified. This phase occurs a few hours after infection, well before the onset of SV40 DNA replication and the synthesis of SV40-specific early proteins.</ab>
<no>LR: 20061115; JID: 0110674; 0 (DNA, Viral); EC 3.1.21.- (DNA Restriction Enzymes); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 6324466; 0042-6822(84)90278-2 [pii]</an>
<la>eng</la>
<sf>Comparative Study; Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6324466</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1804</id>
<a1>Hamilton,H.</a1>
<a1>Gomos,J.</a1>
<a1>Berns,K. I.</a1>
<a1>Falck-Pedersen,E.</a1>
<t1>Adeno-associated virus site-specific integration and AAVS1 disruption</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>2004</yr>
<fd>Aug</fd>
<vo>78</vo>
<is>15</is>
<sp>7874</sp>
<op>7882</op>
<k1>Chromosome Mapping</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>Dependovirus/genetics</k1>
<k1>Gene Amplification</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Replication Origin</k1>
<k1>Virus Integration</k1>
<ab>Adeno-associated virus (AAV) is a single-stranded DNA virus with a unique biphasic lifestyle consisting of both a productive and a latent phase. Typically, the productive phase requires coinfection with a helper virus, for instance adenovirus, while the latent phase dominates in healthy cells. In the latent state, AAV is found integrated site specifically into the host genome at chromosome 19q13.4 qtr (AAVS1), the only animal virus known to integrate in a defined location. In this study we investigated the latent phase of serotype 2 AAV, focusing on three areas: AAV infection, rescue, and integration efficiency as a function of viral multiplicity of infection (MOI); efficiency of site-specific integration; and disruption of the AAVS1 locus. As expected, increasing the AAV MOI resulted in an increase in the percentage of cells infected, with 80% of cells infected at an MOI of 10. Additional MOI only marginally effected a further increase in percentage of infected cells. In contrast to infection, we found very low levels of integration at MOIs of less than 10. At an MOI of 10, at which 80% of cells are infected, less than 5% of clonal cell lines contained integrated AAV DNA. At an MOI of 100 or greater, however, 35 to 40% of clonal cell lines contained integrated AAV DNA. Integration and the ability to rescue viral genomes were highly correlated. Analysis of integrated AAV indicated that essentially all integrants were AAVS1 site specific. Although maximal integration efficiency approached 40% of clonal cell lines (essentially 50% of infected cells), over 80% of cell lines contained a genomic disruption at the AAVS1 integration locus on chromosome 19 ( approximately 100% of infected cells). Rep expression by itself and in the presence of a plasmid integration substrate was able to mediate this disruption of the AAVS1 site. We further characterized the disruption event and demonstrated that it resulted in amplification of the AAVS1 locus. The data are consistent with a revised model of AAV integration that includes preliminary expansion of a defined region in AAVS1.</ab>
<no>LR: 20091118; GR: R01GM067102/GM/NIGMS NIH HHS/United States; JID: 0113724; OID: NLM: PMC446113; ppublish</no>
<pp>United States</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Molecular Biology Program, Weill Medical College of Cornell University, New York, NY 10021, USA.</ad>
<an>PMID: 15254160; 78/15/7874 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1128/JVI.78.15.7874-7882.2004</do>
<ol>Unknown(0)</ol>
<pmid>15254160</pmid>
<pmcid>PMC446113</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1877</id>
<a1>Hauswirth,W. W.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus DNA replication: nonunit-length molecules</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1979</yr>
<fd>Feb</fd>
<vo>93</vo>
<is>1</is>
<sp>57</sp>
<op>68</op>
<k1>DNA Replication</k1>
<k1>DNA, Viral/analysis/biosynthesis</k1>
<k1>Dependovirus/genetics/metabolism</k1>
<k1>Genes, Viral</k1>
<k1>Nucleic Acid Conformation</k1>
<no>LR: 20061115; JID: 0110674; 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 219605</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>219605</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1881</id>
<a1>Hauswirth,W. W.</a1>
<a1>Berns,K. I.</a1>
<t1>Origin and termination of adeno-associated virus DNA replication</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1977</yr>
<fd>May 15</fd>
<vo>78</vo>
<is>2</is>
<sp>488</sp>
<op>499</op>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>DNA Replication</k1>
<k1>DNA Restriction Enzymes/metabolism</k1>
<k1>DNA, Viral/analysis/biosynthesis</k1>
<k1>Deoxyribonucleases/metabolism</k1>
<k1>Exonucleases/metabolism</k1>
<k1>Nucleotides/analysis</k1>
<k1>Satellite Viruses/analysis/metabolism</k1>
<no>LR: 20061115; JID: 0110674; 0 (DNA, Viral); 0 (Nucleotides); EC 3.1.- (Deoxyribonucleases); EC 3.1.- (Exonucleases); EC 3.1.21.- (DNA Restriction Enzymes); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 867815</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>867815</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1806</id>
<a1>Hauswirth,W. W.</a1>
<a1>Li,Q.</a1>
<a1>Raisler,B.</a1>
<a1>Timmers,A. M.</a1>
<a1>Berns,K. I.</a1>
<a1>Flannery,J. G.</a1>
<a1>LaVail,M. M.</a1>
<a1>Lewin,A. S.</a1>
<t1>Range of retinal diseases potentially treatable by AAV-vectored gene therapy</t1>
<jf>Novartis Foundation symposium</jf>
<jo>Novartis Found.Symp.</jo>
<yr>2004</yr>
<vo>255</vo>
<sp>179</sp>
<op>88; discussion 188-94</op>
<k1>Animals</k1>
<k1>Dependovirus</k1>
<k1>Eye Proteins</k1>
<k1>Gene Therapy</k1>
<k1>Genes, Dominant</k1>
<k1>Genes, Recessive</k1>
<k1>Genetic Vectors</k1>
<k1>Glial Cell Line-Derived Neurotrophic Factor</k1>
<k1>Mice</k1>
<k1>Nerve Growth Factors/genetics/metabolism</k1>
<k1>Proteins/genetics/metabolism</k1>
<k1>RNA, Catalytic</k1>
<k1>Retinal Diseases/genetics/therapy</k1>
<k1>Retinal Neovascularization/therapy</k1>
<k1>Serpins/genetics/metabolism</k1>
<ab>Viable strategies for retinal gene therapy must be designed to cope with the genetic nature of the disease and/or the primary pathologic process responsible for retinal malfunction. For dominant gene defects the aim must be to destroy the presumably toxic gene product, for recessive gene defects the direct approach aims to provide a wild-type copy of the gene to the affected retinal cell type, and for diseases of either complex or unknown genetic origin, more general cell survival strategies that deal with preserving affected retinal cells are often the best and only option. Hence examples of each type of therapy will be briefly discussed in several animal models, including ribozyme therapy for autosomal dominant retinitis pigmentosa in the transgenic P23H opsin rat, beta-PDE gene augmentation therapy for autosomal recessive retinitis pigmentosa in the rd mouse, glial cell-derived neurotrophic factor (GDNF) gene therapy for autosomal dominant RP in the transgenic S334ter opsin rat and pigment epithelial cell-derived neurotrophic factor (PEDF) gene therapy for neovascular retinal disease in rodents. Each employs a recombinant AAV vectored passenger gene controlled by one of several promoters supporting either photoreceptor-specific expression or more general retinal cell expression depending on the therapeutic requirements.</ab>
<no>LR: 20071114; GR: EY01919/EY/NEI NIH HHS/United States; GR: EY06842/EY/NEI NIH HHS/United States; GR: EY11123/EY/NEI NIH HHS/United States; GR: EY11596/EY/NEI NIH HHS/United States; GR: EY13101/EY/NEI NIH HHS/United States; GR: NS36302/NS/NINDS NIH HHS/United States; JID: 9807767; 0 (Eye Proteins); 0 (Gdnf protein, mouse); 0 (Glial Cell Line-Derived Neurotrophic Factor); 0 (Nerve Growth Factors); 0 (Proteins); 0 (RNA, Catalytic); 0 (Serpins); 0 (pigment epithelium-derived factor); RF: 32; ppublish</no>
<pp>England</pp>
<sn>1528-2511; 1528-2511</sn>
<ad>Department of Molecular Genetics, University of Florida, Gainesville, FL, USA.</ad>
<an>PMID: 14750604</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>14750604</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1840</id>
<a1>Hong,G.</a1>
<a1>Ward,P.</a1>
<a1>Berns,K. I.</a1>
<t1>Intermediates of adeno-associated virus DNA replication in vitro</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1994</yr>
<fd>Mar</fd>
<vo>68</vo>
<is>3</is>
<sp>2011</sp>
<op>2015</op>
<k1>DNA Replication</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>Dependovirus/genetics/growth &amp; development</k1>
<k1>Models, Genetic</k1>
<k1>Restriction Mapping</k1>
<k1>Virus Replication</k1>
<ab>Intermediates of adeno-associated virus type 2 (AAV) DNA replication in an in vitro assay have been characterized. The assay involves rescue and replication of an AAV insert in pBR322. Intermediates were shown to be duplex molecules in which at least one terminus was in the extended configuration, in contrast to the hairpinned ends seen after rescue in the absence of AAV DNA replication. Also present were linear double-stranded dimers, which were characterized as either head-to-head or tail-to-tail tandems; no head-to-tail dimers were detected. The results are in accord with the current model of AAV DNA replication.</ab>
<no>LR: 20091118; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); OID: NLM: PMC236668; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>W. R. Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 8107263</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8107263</pmid>
<pmcid>PMC236668</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1844</id>
<a1>Hong,G.</a1>
<a1>Ward,P.</a1>
<a1>Berns,K. I.</a1>
<t1>In vitro replication of adeno-associated virus DNA</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1992</yr>
<fd>May 15</fd>
<vo>89</vo>
<is>10</is>
<sp>4673</sp>
<op>4677</op>
<k1>Adenoviruses, Human/genetics</k1>
<k1>Blotting, Southern</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/biosynthesis/genetics/isolation &amp; purification</k1>
<k1>Dependovirus/genetics</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Models, Genetic</k1>
<k1>Plasmids</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Transfection</k1>
<ab>An in vitro assay for adeno-associated virus (AAV) DNA replication has been developed. The substrate is a plasmid containing the duplex form of AAV DNA in pBR322. The AAV insert is excised or rescued from the plasmid by extracts of uninfected cells. Replication was assayed by production of full-length excised AAV DNA resistant to Dpn I digestion. The following results were obtained. (i) Only extracts of cells coinfected with AAV and adenovirus replicated the excised insert. (ii) Density label experiments showed semiconservative replication. (iii) Only the excised AAV insert was replicated; pBR322 sequences were not. (iv) Replication was dependent on the presence of the AAV terminal repeat. (v) If the terminal 55 bases were deleted from both ends of the AAV insert, no rescue took place: replication occurred and both AAV and pBR322 sequences were replicated. We conclude that the AAV terminal repeat is essential for DNA replication but that under some conditions an initiation mechanism that does not involve hairpin priming may be used.</ab>
<no>LR: 20081120; GR: AI22251/AI/NIAID NIH HHS/United States; GR: AI26122/AI/NIAID NIH HHS/United States; JID: 7505876; 0 (DNA, Viral); OID: NLM: PMC49145; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Microbiology, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 1316616</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1316616</pmid>
<pmcid>PMC49145</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1802</id>
<a1>Kang,S. H.</a1>
<a1>Levings,P. P.</a1>
<a1>Andersen,F.</a1>
<a1>Laipis,P. J.</a1>
<a1>Berns,K. I.</a1>
<a1>Zori,R. T.</a1>
<a1>Bungert,J.</a1>
<t1>Locus control region elements HS2 and HS3 in combination with chromatin boundaries confer high-level expression of a human beta-globin transgene in a centromeric region</t1>
<jf>Genes to cells : devoted to molecular &amp; cellular mechanisms</jf>
<jo>Genes Cells</jo>
<yr>2004</yr>
<fd>Nov</fd>
<vo>9</vo>
<is>11</is>
<sp>1043</sp>
<op>1053</op>
<k1>Animals</k1>
<k1>Centromere/genetics</k1>
<k1>Chickens</k1>
<k1>Chromatin/physiology</k1>
<k1>Globins/genetics</k1>
<k1>Humans</k1>
<k1>Locus Control Region</k1>
<k1>Mice</k1>
<k1>Mice, Transgenic</k1>
<k1>Transgenes</k1>
<ab>Expression constructs are subject to position-effects in transgenic assays unless they harbour elements that protect them from negative or positive influences exerted by chromatin at the site of integration. Locus control regions (LCRs) and boundary elements are able to protect from position effects by preventing heterochromatization of linked genes. The LCR in the human beta-globin gene locus is located far upstream of the genes and composed of several erythroid specific DNase I hypersensitive (HS) sites. Previous studies demonstrated that the LCR HS sites act synergistically to confer position-independent and high-level globin gene expression at different integration sites in transgenic mice. Here we show that LCR HS sites 2 and 3, in combination with boundary elements derived from the chicken beta-globin gene locus, confer high-level human beta-globin gene expression in different chromosomal integration sites in transgenic mice. Moreover, we found that the construct is accessible to nucleases and highly expressed when integrated in a centromeric region. These results demonstrate that the combination of enhancer, chromatin opening and boundary activities can establish independent expression units when integrated into chromatin.</ab>
<no>LR: 20071114; GR: DK058209/DK/NIDDK NIH HHS/United States; GR: DK52356/DK/NIDDK NIH HHS/United States; JID: 9607379; 0 (Chromatin); 9004-22-2 (Globins); ppublish</no>
<pp>England</pp>
<sn>1356-9597; 1356-9597</sn>
<ad>Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida 32610, USA.</ad>
<an>PMID: 15507116; GTC788 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1111/j.1365-2443.2004.00788.x</do>
<ol>Unknown(0)</ol>
<pmid>15507116</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1850</id>
<a1>Kotin,R. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Organization of adeno-associated virus DNA in latently infected Detroit 6 cells</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1989</yr>
<fd>Jun</fd>
<vo>170</vo>
<is>2</is>
<sp>460</sp>
<op>467</op>
<k1>Base Sequence</k1>
<k1>Blotting, Southern</k1>
<k1>Cell Line</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA Probes</k1>
<k1>DNA, Viral/analysis/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Nucleic Acid Hybridization</k1>
<k1>Restriction Mapping</k1>
<ab>The DNA of a human dependovirus, adeno-associated virus (AAV), integrates into the cellular genome under conditions nonpermissive for viral DNA replication. The AAV DNA can be rescued from the cellular genome by superinfection with a helper virus, e.g., adenovirus. To characterize the organization of the proviral DNA in greater detail, we isolated three proviral subfragments from a latently infected human cell line. Our findings, based on sequence analysis, restriction enzyme mapping, and genomic blots, demonstrate that the viral terminal repeats (trs) are present at or near the cellular/viral DNA junctions, but significant deletions of the tr sequences have occurred. One of the proviral clones has extensive rearrangements which apparently occurred by nonhomologous recombination. The tail-to-tail arrangement of one of the proviral clones is consistent with limited DNA replication prior to integration by a mechanism similar to that seen in a productive infection. Although there are BamH1 fragments in the cell line we have characterized, which are the right size to have come from a head-to-tail tandem repeat, critical double digests show no evidence for the presence of a head-to-tail tandem repeat of wild-type proviral DNA. Use of probes derived from the flanking cellular DNA enabled us to determine that in this cell line the viral DNA had integrated into a site composed of nonrepetitive sequences.</ab>
<no>LR: 20071114; GENBANK/M27085; GENBANK/M27086; GR: A.I. 22251/PHS HHS/United States; JID: 0110674; 0 (DNA Probes); 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<ad>Department of Microbiology, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 2543124</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2543124</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1843</id>
<a1>Kotin,R. M.</a1>
<a1>Linden,R. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination</t1>
<jf>The EMBO journal</jf>
<jo>EMBO J.</jo>
<yr>1992</yr>
<fd>Dec</fd>
<vo>11</vo>
<is>13</is>
<sp>5071</sp>
<op>5078</op>
<k1>Base Sequence</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>Dependovirus/physiology</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Recombination, Genetic</k1>
<k1>TATA Box</k1>
<k1>Transcription, Genetic</k1>
<k1>Virus Integration</k1>
<ab>The human parvovirus, adeno-associated virus (AAV), has been shown to integrate preferentially into human chromosome 19 q13.3-qter. The human target sequence for AAV integration (AAVS1) was cloned and sequenced. By analysis of the proviral junctions it was determined that integration of the AAV DNA occurred via a non-homologous recombination pathway although there were either four or five identical nucleotides at the junctions. Integration was a multistep, concerted process that resulted in cellular sequence rearrangements. The sequence of the integration locus was analyzed for possible recombination signals. Direct repeats at a much greater than random occurrence were found distributed non-uniformly throughout the AAVS1 sequence. A CpG island containing transcription factor binding site elements is suggestive of a TATA-less promoter. Evidence for transcriptional activity was provided by PCR amplification of reverse transcribed RNA.</ab>
<no>LR: 20081121; GENBANK/D13199; GENBANK/D13200; GENBANK/D13201; GENBANK/D13202; GENBANK/D13203; GENBANK/M94783; GENBANK/M94784; GENBANK/M94785; GENBANK/S51329; GENBANK/X68109; GR: AI 22251/AI/NIAID NIH HHS/United States; JID: 8208664; 0 (DNA, Viral); 9007-49-2 (DNA); OID: NLM: PMC556985; ppublish</no>
<pp>ENGLAND</pp>
<sn>0261-4189; 0261-4189</sn>
<ad>Molecular Hematology Branch, National Institutes of Health, Bethesda, MD 20892.</ad>
<an>PMID: 1334463</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1334463</pmid>
<pmcid>PMC556985</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1845</id>
<a1>Kotin,R. M.</a1>
<a1>Menninger,J. C.</a1>
<a1>Ward,D. C.</a1>
<a1>Berns,K. I.</a1>
<t1>Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter</t1>
<jf>Genomics</jf>
<jo>Genomics</jo>
<yr>1991</yr>
<fd>Jul</fd>
<vo>10</vo>
<is>3</is>
<sp>831</sp>
<op>834</op>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>DNA, Viral/genetics/isolation &amp; purification</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>Recombination, Genetic</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<ab>A human parvovirus, adeno-associated virus (AAV), is unique among eukaryotic DNA viruses in its ability to integrate site specifically into a defined region of human chromosome 19. In this study we used in situ hybridization to visualized directly the site of AAV DNA integration in latently infected human cell lines and normal human cells.</ab>
<no>LR: 20071114; GENBANK/M54997; GENBANK/M60837; GENBANK/M61178; GENBANK/M61179; GENBANK/M61180; GENBANK/M61181; GENBANK/S54791; GENBANK/S54795; GENBANK/S54803; GENBANK/S55393; GR: AI-22251/AI/NIAID NIH HHS/United States; GR: HG00246/HG/NHGRI NIH HHS/United States; GR: HG00272/HG/NHGRI NIH HHS/United States; JID: 8800135; 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0888-7543; 0888-7543</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 1653762</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1653762</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1848</id>
<a1>Kotin,R. M.</a1>
<a1>Siniscalco,M.</a1>
<a1>Samulski,R. J.</a1>
<a1>Zhu,X. D.</a1>
<a1>Hunter,L.</a1>
<a1>Laughlin,C. A.</a1>
<a1>McLaughlin,S.</a1>
<a1>Muzyczka,N.</a1>
<a1>Rocchi,M.</a1>
<a1>Berns,K. I.</a1>
<t1>Site-specific integration by adeno-associated virus</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1990</yr>
<fd>Mar</fd>
<vo>87</vo>
<is>6</is>
<sp>2211</sp>
<op>2215</op>
<k1>Cell Line</k1>
<k1>Chromosomes, Human</k1>
<k1>Clone Cells</k1>
<k1>DNA Probes</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Genes, Viral</k1>
<k1>Humans</k1>
<k1>KB Cells</k1>
<k1>Lysogeny</k1>
<k1>Proviruses/genetics</k1>
<ab>Cellular sequences flanking integrated copies of the adeno-associated virus (AAV) genome were isolated from a latently infected clonal human cell line and used to probe genomic blots derived from an additional 21 independently derived clones of human cells latently infected with AAV. In genomic blots of uninfected human cell lines and of primary human tissue, each flanking-sequence probe hybridized to unique bands, but in 15 of the 22 latently infected clones the flanking sequences hybridized not only to the original fragments but also to a total of 36 additional species. AAV probes also hybridized to 22 of these new bands, representing 11 of the 15 positive clones, but never to the fragment characteristic of uninfected cell DNA. From these data we conclude that the AAV genome preferentially integrates into a specific region of the cellular genome. We have determined that the integration site is unique to chromosome 19 by somatic cell hybrid mapping, and this sequence has been isolated from uninfected human DNA.</ab>
<no>LR: 20091118; GR: AI22251/AI/NIAID NIH HHS/United States; GR: AI25530/AI/NIAID NIH HHS/United States; GR: GM37090/GM/NIGMS NIH HHS/United States; GR: etc.; JID: 7505876; 0 (DNA Probes); 0 (DNA, Viral); OID: NLM: PMC53656; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 2156265</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2156265</pmid>
<pmcid>PMC53656</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1854</id>
<a1>Labow,M. A.</a1>
<a1>Berns,K. I.</a1>
<t1>The adeno-associated virus rep gene inhibits replication of an adeno-associated virus/simian virus 40 hybrid genome in cos-7 cells</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1988</yr>
<fd>May</fd>
<vo>62</vo>
<is>5</is>
<sp>1705</sp>
<op>1712</op>
<k1>Adenoviridae/genetics/physiology</k1>
<k1>Animals</k1>
<k1>Cell Line</k1>
<k1>Chimera</k1>
<k1>Chromosome Deletion</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>Genes, Viral</k1>
<k1>Humans</k1>
<k1>Mutation</k1>
<k1>Plasmids</k1>
<k1>RNA, Viral/analysis</k1>
<k1>Simian virus 40/genetics/physiology</k1>
<k1>Transfection</k1>
<k1>Virus Replication</k1>
<ab>A hybrid adeno-associated virus (AAV)/simian virus 40 (SV40) genome is described. In this construct SV40 regulatory sequences, including the early promoter/enhancers and origin of DNA replication, were substituted for the AAV p5 promoter, which normally controls expression of the AAV rep gene. The hybrid genome was phenotypically indistinguishable from wild-type AAV in human cells in the presence or absence of helper virus. Upon transfection into cos-7 cells, which constitutively produced the SV40 tumor antigen, the genome replicated as a plasmid when the SV40 origin was used, although with a low efficiency compared with that of a non-AAV/SV40 replicon. The low level of replication was due to an inhibitory effect of an AAV rep gene product and was specific for replicons containing AAV sequences. Target AAV sequences required for inhibition by rep appeared to reside in the terminal repetitions since deletion of these sequences allowed efficient replication in the presence of the rep gene. The possible role for negative autoregulation of AAV DNA replication in latent infection and helper-dependent replication by AAV is discussed.</ab>
<no>LR: 20091118; GR: AI 22251/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); 0 (RNA, Viral); OID: NLM: PMC253208; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Molecular Biology, Princeton University, New Jersey 08544.</ad>
<an>PMID: 2833621</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>2833621</pmid>
<pmcid>PMC253208</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1855</id>
<a1>Labow,M. A.</a1>
<a1>Graf,L. H.,Jr</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus gene expression inhibits cellular transformation by heterologous genes</t1>
<jf>Molecular and cellular biology</jf>
<jo>Mol.Cell.Biol.</jo>
<yr>1987</yr>
<fd>Apr</fd>
<vo>7</vo>
<is>4</is>
<sp>1320</sp>
<op>1325</op>
<k1>Acetyltransferases/genetics</k1>
<k1>Adenovirus Early Proteins</k1>
<k1>Animals</k1>
<k1>Cell Line</k1>
<k1>Cell Transformation, Neoplastic</k1>
<k1>Chloramphenicol O-Acetyltransferase</k1>
<k1>DNA Replication</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genes</k1>
<k1>Genes, Viral</k1>
<k1>Melanoma, Experimental</k1>
<k1>Mice</k1>
<k1>Mutation</k1>
<k1>Oncogene Proteins, Viral/genetics</k1>
<k1>Plasmids</k1>
<k1>Transfection</k1>
<ab>In this paper we report that adeno-associated virus (AAV) genomes inhibit stable transformation by several dominant selectable marker genes upon cotransfection into mouse tissue culture cells. Cotransfection of AAV genomes also inhibited the expression of pSV2cat in transient assays. In both cases, the inhibitory effect was independent of AAV DNA replication but required the AAV p5 and p19 genes, which encode proteins required for AAV DNA replication and regulation of AAV gene expression. Finally, addition of a cloned E4 gene in the transfection experiments partially blocked the AAV-mediated inhibitory activities.</ab>
<no>LR: 20091118; GR: AI 22251/AI/NIAID NIH HHS/United States; JID: 8109087; 0 (Adenovirus Early Proteins); 0 (Oncogene Proteins, Viral); EC 2.3.1.- (Acetyltransferases); EC 2.3.1.28 (Chloramphenicol O-Acetyltransferase); OID: NLM: PMC365216; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0270-7306; 0270-7306</sn>
<an>PMID: 3037312</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>3037312</pmid>
<pmcid>PMC365216</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1858</id>
<a1>Labow,M. A.</a1>
<a1>Hermonat,P. L.</a1>
<a1>Berns,K. I.</a1>
<t1>Positive and negative autoregulation of the adeno-associated virus type 2 genome</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1986</yr>
<fd>Oct</fd>
<vo>60</vo>
<is>1</is>
<sp>251</sp>
<op>258</op>
<k1>DNA Replication</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Gene Expression Regulation</k1>
<k1>Genes, Viral</k1>
<k1>RNA, Messenger/genetics</k1>
<k1>RNA, Viral/genetics</k1>
<k1>Transcription, Genetic</k1>
<k1>Virus Replication</k1>
<ab>The defective human parvovirus, adeno-associated virus (AAV), requires multiple functions provided by a coinfecting helper virus for viral replication. In addition, it has recently been shown that at least one AAV gene is also required for AAV DNA replication. In this paper, we investigate the autoregulation of the AAV genome by analyzing the expression of mutant AAV genomes upon transfection into adenovirus-infected human cells. Evidence is presented which indicates that the AAV genome regulates its own gene expression in at least two ways. First, either the AAV p5 gene or both the p5 and p19 genes appear to encode a trans activator of AAV transcription. Frameshift mutations within the p5 or p19 gene severely inhibited the synthesis and accumulation of all AAV transcripts. The defective accumulation of transcripts could be complemented in trans, in a manner independent of DNA replication, by cotransfection with a capsid deletion mutant. Second, evidence is presented which suggests that the p5 and p19 genes contain negative cis-active regulatory elements. Deletion of sequences within the p5 and p19 genes enhanced the accumulation of the p5 transcript in cis upon complementation with an AAV capsid deletion mutant, whereas certain deletions enhanced p40 RNA accumulation in the absence of trans activation by the p5 gene.</ab>
<no>LR: 20091118; GR: AI 22251/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (RNA, Messenger); 0 (RNA, Viral); OID: NLM: PMC253923; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 3018288</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>3018288</pmid>
<pmcid>PMC253923</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1861</id>
<a1>LeFebvre,R. B.</a1>
<a1>Berns,K. I.</a1>
<t1>Unique events in parvovirus replication</t1>
<jf>Microbiological sciences</jf>
<jo>Microbiol.Sci.</jo>
<yr>1984</yr>
<fd>Oct</fd>
<vo>1</vo>
<is>7</is>
<sp>163</sp>
<op>167</op>
<k1>Base Sequence</k1>
<k1>DNA Replication/genetics</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Models, Genetic</k1>
<k1>Molecular Sequence Data</k1>
<k1>Parvoviridae/genetics/physiology</k1>
<k1>Virus Replication/genetics</k1>
<ab>The single-stranded parvovirus genome is characterized by a palindromic sequence at the 3&amp;#39; terminus. This structure serves uniquely as a primer for DNA replication.</ab>
<no>LR: 20051116; JID: 8510101; 0 (DNA, Viral); RF: 22; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0265-1351; 0265-1351</sn>
<ad>Department of Immunology and Medical Microbiology, College of Medicine, University of Florida, J. Hillis Miller Health Center, Gainesville 32610.</ad>
<an>PMID: 6101112</an>
<la>eng</la>
<sf>Journal Article; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6101112</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1863</id>
<a1>Lefebvre,R. B.</a1>
<a1>Riva,S.</a1>
<a1>Berns,K. I.</a1>
<t1>Conformation takes precedence over sequence in adeno-associated virus DNA replication</t1>
<jf>Molecular and cellular biology</jf>
<jo>Mol.Cell.Biol.</jo>
<yr>1984</yr>
<fd>Jul</fd>
<vo>4</vo>
<is>7</is>
<sp>1416</sp>
<op>1419</op>
<k1>Adenoviruses, Human/genetics</k1>
<k1>Base Sequence</k1>
<k1>Chromosome Deletion</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Humans</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Plasmids</k1>
<k1>Transfection</k1>
<k1>Virus Replication</k1>
<ab>Deletion of an 11-base symmetrical sequence in the inverted terminal repetition of the adeno-associated virus 2 genome inhibits DNA replication. Substitution of either an 8- or a 12-base symmetrical sequence unrelated to the original 11-base sequence restores DNA replication.</ab>
<no>LR: 20091118; GENBANK/K01624; GENBANK/K01625; GR: AI 16326/AI/NIAID NIH HHS/United States; JID: 8109087; 0 (DNA, Viral); OID: NLM: PMC368925; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0270-7306; 0270-7306</sn>
<an>PMID: 6504049</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6504049</pmid>
<pmcid>PMC368925</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1841</id>
<a1>Leonard,C. J.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus type 2: a latent life cycle</t1>
<jf>Progress in nucleic acid research and molecular biology</jf>
<jo>Prog.Nucleic Acid Res.Mol.Biol.</jo>
<yr>1994</yr>
<vo>48</vo>
<sp>29</sp>
<op>52</op>
<k1>Animals</k1>
<k1>Base Sequence</k1>
<k1>Cell Line</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Gene Expression Regulation, Viral/genetics</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Parvoviridae Infections/genetics</k1>
<k1>Plasmids</k1>
<k1>Virus Latency/genetics</k1>
<no>LR: 20071114; GR: AI22251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0102753; RF: 140; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0079-6603; 0079-6603</sn>
<ad>W. R. Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 7938552</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>7938552</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1839</id>
<a1>Leonard,C. J.</a1>
<a1>Berns,K. I.</a1>
<t1>Cloning, expression, and partial purification of Rep78: an adeno-associated virus replication protein</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1994</yr>
<fd>May 1</fd>
<vo>200</vo>
<is>2</is>
<sp>566</sp>
<op>573</op>
<k1>Cell Nucleus/chemistry</k1>
<k1>Cloning, Molecular</k1>
<k1>DNA-Binding Proteins/biosynthesis/genetics/isolation &amp; purification/pharmacology</k1>
<k1>Dependovirus/drug effects/growth &amp; development</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Recombinant Proteins/biosynthesis</k1>
<k1>Transfection</k1>
<k1>Viral Proteins/biosynthesis/genetics/isolation &amp; purification/pharmacology</k1>
<k1>Virus Replication/drug effects</k1>
<ab>Using the vaccinia virus/T7-RNA polymerase transient protein expression system, the AAV Rep78 protein was expressed in mammalian cells. Rep78 protein was found localized primarily to the nucleus of cells. Maximal steady-state protein levels were reached as early as 12 hr postinfection, with no discernable increase at later time points. The Rep78 protein has been partially purified from nuclear extracts of the expression system. We have successfully used the cloned, purified Rep78 protein to complement an uninfected HeLa cell extract in an in vitro AAV DNA replication assay. Rep78-containing fractions are sufficient to make an uninfected HeLa cell extract competent for AAV DNA replication.</ab>
<no>LR: 20071114; GR: AI22251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0110674; 0 (DNA-Binding Proteins); 0 (Recombinant Proteins); 0 (Viral Proteins); 137750-19-7 (rep proteins, Adeno-associated virus 2); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<ad>Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 8178443; S0042-6822(84)71219-0 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1006/viro.1994.1219</do>
<ol>Unknown(0)</ol>
<pmid>8178443</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1816</id>
<a1>Linden,R. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Molecular biology of adeno-associated viruses</t1>
<jf>Contributions to microbiology</jf>
<jo>Contrib.Microbiol.</jo>
<yr>2000</yr>
<vo>4</vo>
<sp>68</sp>
<op>84</op>
<k1>Animals</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>Dependovirus/classification/genetics</k1>
<k1>Genome, Viral</k1>
<k1>Humans</k1>
<k1>Molecular Biology</k1>
<k1>Transcription, Genetic</k1>
<no>LR: 20051116; JID: 9815689; 0 (DNA, Viral); RF: 100; ppublish</no>
<pp>SWITZERLAND</pp>
<sn>1420-9519; 1420-9519</sn>
<ad>Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, N.Y., USA.</ad>
<an>PMID: 10941571</an>
<la>eng</la>
<sf>Journal Article; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>10941571</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1825</id>
<a1>Linden,R. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Site-specific integration by adeno-associated virus: a basis for a potential gene therapy vector</t1>
<jf>Gene therapy</jf>
<jo>Gene Ther.</jo>
<yr>1997</yr>
<fd>Jan</fd>
<vo>4</vo>
<is>1</is>
<sp>4</sp>
<op>5</op>
<k1>Dependovirus</k1>
<k1>Gene Therapy/methods</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Mutagenesis, Site-Directed</k1>
<no>LR: 20060421; JID: 9421525; ppublish</no>
<pp>ENGLAND</pp>
<sn>0969-7128; 0969-7128</sn>
<an>PMID: 9068788</an>
<la>eng</la>
<sf>Editorial; IM</sf>
<do>10.1038/sj.gt.3300357</do>
<ol>Unknown(0)</ol>
<pmid>9068788</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1827</id>
<a1>Linden,R. M.</a1>
<a1>Ward,P.</a1>
<a1>Giraud,C.</a1>
<a1>Winocour,E.</a1>
<a1>Berns,K. I.</a1>
<t1>Site-specific integration by adeno-associated virus</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1996</yr>
<fd>Oct 15</fd>
<vo>93</vo>
<is>21</is>
<sp>11288</sp>
<op>11294</op>
<k1>Base Sequence</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>DNA/chemistry</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/chemistry</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Genetic Vectors</k1>
<k1>Humans</k1>
<k1>Models, Genetic</k1>
<k1>Molecular Sequence Data</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Recombination, Genetic</k1>
<k1>Virus Integration</k1>
<k1>Virus Replication</k1>
<ab>Adeno-associated virus (AAV) has attracted considerable interest as a potential vector for gene delivery. Wild-type virus is notable for the lack of association with any human disease and the ability to stably integrate its genome in a site-specific manner in a locus on human chromosome 19 (AAVS1). Use of a functional model system for AAV DNA integration into AAVS1 has allowed us to conclude that the recombination event is directed by cellular DNA sequences. Recombinant junctions isolated from our integration assay were analyzed and showed characteristics similar to those found in latently infected cell lines. The minimal DNA signals within AAVS1 required for targeted integration were identified and shown to contain functional motifs of the viral origin of replication. A replication mediated model of AAV DNA integration is proposed.</ab>
<no>LR: 20091118; GR: AI22251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 7505876; 0 (DNA, Viral); 9007-49-2 (DNA); RF: 37; OID: NLM: PMC38050; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, NY 10021, USA.</ad>
<an>PMID: 8876128</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; Review; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8876128</pmid>
<pmcid>PMC38050</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1828</id>
<a1>Linden,R. M.</a1>
<a1>Winocour,E.</a1>
<a1>Berns,K. I.</a1>
<t1>The recombination signals for adeno-associated virus site-specific integration</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1996</yr>
<fd>Jul 23</fd>
<vo>93</vo>
<is>15</is>
<sp>7966</sp>
<op>7972</op>
<k1>Base Sequence</k1>
<k1>Binding Sites</k1>
<k1>Cell Line</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>DNA Helicases/metabolism</k1>
<k1>DNA, Viral/chemistry/genetics</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genetic Vectors</k1>
<k1>Genotype</k1>
<k1>Humans</k1>
<k1>Models, Genetic</k1>
<k1>Molecular Sequence Data</k1>
<k1>Mutagenesis, Insertional</k1>
<k1>Mutagenesis, Site-Directed</k1>
<k1>Oligodeoxyribonucleotides</k1>
<k1>Recombination, Genetic</k1>
<k1>Signal Transduction</k1>
<k1>Trans-Activators/metabolism</k1>
<k1>Virus Integration</k1>
<ab>The adeno-associated virus (AAV) genome integrates site specifically into a defined region of human chromosome 19 (termed AAVS1). Using a functional assay for AAV integration into AAVS1 DNA propagated as an episome, we obtained evidence that a 33-nucleotide AAVS1 DNA sequence contains the minimum signal required for targeted integration. The recombination signal comprises a DNA-binding motif for the AAV regulatory Rep protein [Rep binding site (RBS)] separated by an eight-nucleotide spacer from a sequence that can act as a substrate for Rep endonucleolytic activity [terminal resolution site (TRS)]. Mutations in either the AAVS1-encoded RBS or TRS elements abort targeted integration. Since both the RBS and TRS elements are present in the viral origin of replication and are required for AAV replication, targeted integration into chromosome 19 AAVS1 DNA may involve a replicative type of recombination that is discussed. An additional chromosome 19 element, which is responsible for DNA rearrangements in episomes propagating AAVS1 DNA, was identified and shown not to be required for AAV episomal integration, despite its location adjacent to the recombination signal.</ab>
<no>LR: 20091118; GR: AI22251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 7505876; 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Oligodeoxyribonucleotides); 0 (Trans-Activators); 0 (replication initiator protein); EC 3.6.1.- (DNA Helicases); OID: NLM: PMC38858; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, NY 10021, USA.</ad>
<an>PMID: 8755586</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8755586</pmid>
<pmcid>PMC38858</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1821</id>
<a1>Longhurst,S. J.</a1>
<a1>Rafferty,J. A.</a1>
<a1>Arrand,J. R.</a1>
<a1>Cortez,N.</a1>
<a1>Giraud,C.</a1>
<a1>Berns,K. I.</a1>
<a1>Fairbairn,L. J.</a1>
<t1>Recombinant adeno-associated virus-mediated expression of O6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>1999</yr>
<fd>Jan 20</fd>
<vo>10</vo>
<is>2</is>
<sp>301</sp>
<op>310</op>
<k1>Antineoplastic Agents, Alkylating/toxicity</k1>
<k1>Base Sequence</k1>
<k1>DNA Primers</k1>
<k1>Dependovirus/genetics</k1>
<k1>Epithelium/drug effects</k1>
<k1>Hematopoietic Stem Cells/drug effects</k1>
<k1>Humans</k1>
<k1>Nitrogen Mustard Compounds/toxicity</k1>
<k1>O(6)-Methylguanine-DNA Methyltransferase/genetics</k1>
<k1>Plasmids</k1>
<k1>Recombination, Genetic</k1>
<k1>Transduction, Genetic</k1>
<k1>Transgenes</k1>
<k1>Tumor Cells, Cultured</k1>
<ab>Recombinant adeno-associated virus (rAAV) encoding the human O6-alkylguanine-DNA-alkyltransferase (hAT) protein and a selectable marker (Neo(r)) was used to transduce human cervical carcinoma (HeLa) cells and erythroleukemic (K562) cells and clones were selected using G418 (0.4 mg/ml). Thirteen HeLa clones were isolated, 9 of which survived for 2-3 months before cell death ensued, presumably owing to the loss of G418 resistance. Northern blot analysis of the remaining four clones, using a neo probe, showed high levels of RNA equivalent in size to the bicistronic RNA expected to be produced from this construct. Analysis of hAT activity showed that 2000-5000 fmol/mg protein was expressed relative to untransduced cells (800-900 fmol/mg protein). Cell survival analysis following exposure to the chloroethylating agent mitozolomide revealed that expression of hAT at levels two- to fourfold higher than background conferred significant resistance (p &amp;lt; 0.001) to the toxic effects of this drug. Two days following infection of K562 cells with the rAAV vector, immunoblot analysis showed that hAT protein was being produced. Three K562 clones, isolated using G418 selection, were studied in detail and were shown to express hAT activities of 1500, 1010, and 890 fmol/mg protein, respectively, at 40 days posttransduction (mock-transduced K562 cells contain &amp;lt;2 fmol of hAT/mg protein). As with HeLa cells, Northern blot analysis showed the production of an appropriately sized transcript and immunoblot analysis indicated that hAT protein was being produced. These clones were assayed for cell survival following exposure to mitozolomide. Expression of hAT at levels 800- to 1500-fold higher than background conferred significant resistance (p &amp;lt; 0.001) to the toxic effects of mitozolomide. We have therefore successfully conferred a protective advantage against mitozolomide toxicity to cells by rAAV-mediated hAT expression.</ab>
<no>LR: 20061115; JID: 9008950; 0 (Antineoplastic Agents, Alkylating); 0 (DNA Primers); 0 (Nitrogen Mustard Compounds); 85622-95-3 (mitozolomide); EC 2.1.1.63 (O(6)-Methylguanine-DNA Methyltransferase); ppublish</no>
<pp>UNITED STATES</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>CRC Section of Haemopoietic Cell and Gene Therapeutics, Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, England.</ad>
<an>PMID: 10022554</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; IM</sf>
<do>10.1089/10430349950019084</do>
<ol>Unknown(0)</ol>
<pmid>10022554</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1873</id>
<a1>Lusby,E.</a1>
<a1>Bohenzky,R.</a1>
<a1>Berns,K. I.</a1>
<t1>Inverted terminal repetition in adeno-associated virus DNA: independence of the orientation at either end of the genome</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1981</yr>
<fd>Mar</fd>
<vo>37</vo>
<is>3</is>
<sp>1083</sp>
<op>1086</op>
<k1>DNA Replication</k1>
<k1>DNA, Single-Stranded</k1>
<k1>DNA, Viral</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genes, Viral</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<ab>Complementary strands of adeno-associated virus DNA labeled with 32P at the 5&amp;#39; ends were separated and then self-annealed to form single-stranded circles stabilized by hydrogen bonds between the complementary sequences in the inverted terminal repetitions. We have previously shown that there are two distinct sequences in the terminal repetition which represent an inversion of the first 125 nucleotides (E. Lusby et al., J. Virol. 34:402-409, 1980; I. S. Spear et al., Virology 24:627-634, 1977). Base pairing between terminal sequences of the same orientation leads to a normal double helical structure. If sequences of the opposite orientation pair, an aberrant secondary structure is formed. HpaII digestion of the self-annealed, single-stranded circles led to labeled terminal fragments that corresponded both to those generated from termini of a normal double helical structure and those generated from an aberrant terminal secondary structure. Thus, the orientation of the terminal repetition at one end of the genome is not influenced by the orientation at the other end.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Single-Stranded); 0 (DNA, Viral); OID: NLM: PMC171108; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 6262528</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6262528</pmid>
<pmcid>PMC171108</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1875</id>
<a1>Lusby,E.</a1>
<a1>Fife,K. H.</a1>
<a1>Berns,K. I.</a1>
<t1>Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1980</yr>
<fd>May</fd>
<vo>34</vo>
<is>2</is>
<sp>402</sp>
<op>409</op>
<k1>Base Sequence</k1>
<k1>DNA Replication</k1>
<k1>DNA Restriction Enzymes</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Dependovirus/analysis/metabolism</k1>
<k1>Models, Biological</k1>
<ab>The inverted terminal repetition in adeno-associated virus type 2 DNA has been sequenced. The terminal repetition contain 145 nucleotides of which the first 125 nucleotides can self-base pair to form a T-shaped hairpin structure. Both restriction endonuclease analysis with SmaI and BglI and direct sequence analysis of the SmaI fragments provide evidence for two sequences in the region of the terminal repetition between nucleotides 44 and 81. The two sequences represent an inversion of the first 125 nucleotides of the terminal repetition. Based on these data a model for adeno-associated virus DNA replication is presented which agrees in detail with a general model for eucaryotic DNA replication originally proposed by Cavalier-Smith (T. Cavalier-Smith, Nature [London] 18:672--684, 1976).</ab>
<no>LR: 20091118; GENBANK/K01624; GENBANK/K01625; JID: 0113724; 0 (DNA, Viral); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC288718; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 6246271</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6246271</pmid>
<pmcid>PMC288718</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1871</id>
<a1>Lusby,E. W.</a1>
<a1>Berns,K. I.</a1>
<t1>Mapping of the 5&amp;#39; termini of two adeno-associated virus 2 RNAs in the left half of the genome</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1982</yr>
<fd>Feb</fd>
<vo>41</vo>
<is>2</is>
<sp>518</sp>
<op>526</op>
<k1>Base Sequence</k1>
<k1>Chromosome Mapping</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genes, Viral</k1>
<k1>RNA, Messenger/genetics</k1>
<k1>RNA, Viral/genetics</k1>
<ab>The left 45% of the adeno-associated virus 2 genome was sequenced. The 5&amp;#39; termini of two adeno-associated virus-specific RNAs were mapped at the nucleotide level within this region of the genome (nucleotides 286 to 288 and 871 to 874). Both of these 5&amp;#39; termini map 31 +/- 2 nucleotides downstream from the start of &amp;quot;TATA&amp;#39; boxes.</ab>
<no>LR: 20091118; GENBANK/J01902; GR: AI16326/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); 0 (RNA, Messenger); 0 (RNA, Viral); OID: NLM: PMC256780; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 6281463</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6281463</pmid>
<pmcid>PMC256780</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1797</id>
<a1>Lutty,G. A.</a1>
<a1>Chan-Ling,T.</a1>
<a1>Phelps,D. L.</a1>
<a1>Adamis,A. P.</a1>
<a1>Berns,K. I.</a1>
<a1>Chan,C. K.</a1>
<a1>Cole,C. H.</a1>
<a1>D&#39;Amore,P. A.</a1>
<a1>Das,A.</a1>
<a1>Deng,W. T.</a1>
<a1>Dobson,V.</a1>
<a1>Flynn,J. T.</a1>
<a1>Friedlander,M.</a1>
<a1>Fulton,A.</a1>
<a1>Good,W. V.</a1>
<a1>Grant,M. B.</a1>
<a1>Hansen,R.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Hardy,R. J.</a1>
<a1>Hinton,D. R.</a1>
<a1>Hughes,S.</a1>
<a1>McLeod,D. S.</a1>
<a1>Palmer,E. A.</a1>
<a1>Patz,A.</a1>
<a1>Penn,J. S.</a1>
<a1>Raisler,B. J.</a1>
<a1>Repka,M. X.</a1>
<a1>Saint-Geniez,M.</a1>
<a1>Shaw,L. C.</a1>
<a1>Shima,D. T.</a1>
<a1>Smith,B. T.</a1>
<a1>Smith,L. E.</a1>
<a1>Tahija,S. G.</a1>
<a1>Tasman,W.</a1>
<a1>Trese,M. T.</a1>
<t1>Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California)</t1>
<jf>Molecular vision</jf>
<jo>Mol.Vis.</jo>
<yr>2006</yr>
<fd>May 23</fd>
<vo>12</vo>
<sp>532</sp>
<op>580</op>
<k1>Humans</k1>
<k1>Infant, Newborn</k1>
<k1>Retinopathy of Prematurity/etiology/therapy</k1>
<ab>The Third International Symposium on Retinopathy of Prematurity (ROP) was convened with the aim of cross fertilizing the horizons of basic and clinical scientists with an interest in the pathogenesis and management of infants with ROP. Ten speakers in the clinical sciences and ten speakers in the basic sciences were recruited on the basis of their research to provide state of the art talks. The meeting was held November 9, 2003 immediately prior to the American Academy of Ophthalmology meeting; scholarships were provided for outreach to developing countries and young investigators. This review contain the summaries of the 20 platform presentations prepared by the authors and the abstracts of presented posters. Each author was asked to encapsulate the current state of understanding, identify areas of controversy, and make recommendations for future research. The basic science presentations included insights into the development of the human retinal vasculature, animal models for ROP, growth factors that affect normal development and ROP, and promising new therapeutic approaches to treating ROP like VEGF targeting, inhibition of proteases, stem cells, ribozymes to silence genes, and gene therapy to deliver antiangiogenic agents. The clinical presentations included new insights into oxygen management, updates on the CRYO-ROP and ETROP studies, visual function in childhood following ROP, the neural retina in ROP, screening for ROP, management of stage 3 and 4 ROP, ROP in the third world, and the complications of ROP in adult life. The meeting resulted in a penetrating exchange between clinicians and basic scientists, which provided great insights for conference attendees. The effect of preterm delivery on the normal cross-talk of neuroretinal and retinal vascular development is a fertile ground for discovering new understanding of the processes involved both in normal development and in retinal neovascular disorders. The meeting also suggested promising potential therapeutic interventions on the horizon for ROP.</ab>
<no>LR: 20061115; JID: 9605351; epublish</no>
<pp>United States</pp>
<sn>1090-0535; 1090-0535</sn>
<ad>Wilmer Ophthalmological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. glutty@jhmi.edu</ad>
<an>PMID: 16735995; v12/a63 [pii]</an>
<la>eng</la>
<sf>Congresses; Research Support, Non-U.S. Gov&#39;t; IM</sf>
<wp>20060523</wp>
<ol>Unknown(0)</ol>
<pmid>16735995</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1842</id>
<a1>Mahy,B. W.</a1>
<a1>Almond,J. W.</a1>
<a1>Berns,K. I.</a1>
<a1>Chanock,R. M.</a1>
<a1>Lvov,D. K.</a1>
<a1>Pettersson,R. F.</a1>
<a1>Schatzmayr,H. G.</a1>
<a1>Fenner,F.</a1>
<t1>The remaining stocks of smallpox virus should be destroyed</t1>
<jf>Science (New York, N.Y.)</jf>
<jo>Science</jo>
<yr>1993</yr>
<fd>Nov 19</fd>
<vo>262</vo>
<is>5137</is>
<sp>1223</sp>
<op>1224</op>
<k1>Biological Specimen Banks</k1>
<k1>Centers for Disease Control and Prevention (U.S.)</k1>
<k1>Containment of Biohazards</k1>
<k1>Genome, Viral</k1>
<k1>Humans</k1>
<k1>Preservation, Biological</k1>
<k1>Smallpox/prevention &amp; control</k1>
<k1>Smallpox Vaccine</k1>
<k1>United States</k1>
<k1>Variola virus/genetics</k1>
<k1>World Health Organization</k1>
<no>LR: 20070319; JID: 0404511; 0 (Smallpox Vaccine); CIN: Science. 1994 Jan 7;263(5143):13. PMID: 8129820; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0036-8075; 0036-8075</sn>
<ad>Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333.</ad>
<an>PMID: 8235651</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8235651</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1817</id>
<a1>Meneses,P.</a1>
<a1>Berns,K. I.</a1>
<a1>Winocour,E.</a1>
<t1>DNA sequence motifs which direct adeno-associated virus site-specific integration in a model system</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>2000</yr>
<fd>Jul</fd>
<vo>74</vo>
<is>13</is>
<sp>6213</sp>
<op>6216</op>
<k1>Binding Sites</k1>
<k1>Cell Line, Transformed</k1>
<k1>DNA Helicases/metabolism</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Humans</k1>
<k1>Models, Biological</k1>
<k1>Mutagenesis, Site-Directed</k1>
<k1>Viral Proteins/metabolism</k1>
<k1>Virus Integration</k1>
<ab>The DNA sequence motifs which direct adeno-associated virus type 2 site-specific integration are being investigated using a shuttle vector, propagated as a stable episome in cultured cell lines, as the target for integration. Previously, we reported that the minimum episomal targeting elements comprise a 16-bp binding motif (Rep binding site [RBS]) for a viral regulatory protein (Rep) separated by a short DNA spacer from a sequence (terminal resolution site [TRS]) that can serve as a substrate for Rep-mediated nicking activity (R. M. Linden, P. Ward, C. Giraud, E. Winocour, and K. I. Berns, Proc. Natl. Acad. Sci. USA 93:11288-11294, 1996; R. M. Linden, E. Winocour, and K. I. Berns, Proc. Natl. Acad. Sci. USA 93:7966-7972, 1996). We now report that episomal integration depends upon both the sequence and the position of the spacer DNA separating the RBS and TRS motifs. The spacer thus constitutes a third element required for site-specific episomal integration.</ab>
<no>LR: 20091118; GR: AI 122251/AI/NIAID NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Viral Proteins); 137750-19-7 (rep proteins, Adeno-associated virus 2); EC 3.6.1.- (DNA Helicases); OID: NLM: PMC112124; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Pathology, Harvard Medical School, Boston, MA 02215, USA.</ad>
<an>PMID: 10846109</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>10846109</pmid>
<pmcid>PMC112124</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1818</id>
<a1>Meneses,P. I.</a1>
<a1>Abrey,L. E.</a1>
<a1>Hajjar,K. A.</a1>
<a1>Gultekin,S. H.</a1>
<a1>Duvoisin,R. M.</a1>
<a1>Berns,K. I.</a1>
<a1>Rosenfeld,M. R.</a1>
<t1>Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth</t1>
<jf>Clinical cancer research : an official journal of the American Association for Cancer Research</jf>
<jo>Clin.Cancer Res.</jo>
<yr>1999</yr>
<fd>Nov</fd>
<vo>5</vo>
<is>11</is>
<sp>3689</sp>
<op>3694</op>
<k1>Animals</k1>
<k1>Brain Neoplasms/blood supply/drug therapy/pathology</k1>
<k1>Cell Division/drug effects</k1>
<k1>Cell Line</k1>
<k1>Cells, Cultured</k1>
<k1>Cloning, Molecular</k1>
<k1>Endothelium, Vascular/cytology/drug effects</k1>
<k1>Female</k1>
<k1>Glioma/blood supply/drug therapy/pathology</k1>
<k1>Humans</k1>
<k1>Microcirculation/drug effects/pathology</k1>
<k1>Neovascularization, Pathologic/prevention &amp; control</k1>
<k1>Peptide Fragments/genetics/therapeutic use/toxicity</k1>
<k1>Plasminogen/genetics/therapeutic use/toxicity</k1>
<k1>Rats</k1>
<k1>Rats, Inbred F344</k1>
<k1>Recombinant Proteins/therapeutic use/toxicity</k1>
<k1>Transfection</k1>
<k1>Umbilical Veins</k1>
<ab>Angiostatin is an endogenous inhibitor of tumor neovascularization that inhibits the proliferation of endothelial cells. Production of sufficient quantities of biologically active angiostatin by the enzymatic cleavage of plasminogen has proven difficult in that it has delayed clinical testing. We have cloned, expressed, and purified a recombinant human angiostatin derivative (K1-3) using a mammalian expression system. Through the addition of a secretory signal and polyhistidine sequence tag, K1-3 can be purified from post-culture medium by simple column chromatography. Purified K1-3 protein is apparently folded in an active conformation, as evidenced by its ability to bind to lysine-Sepharose. In vitro, recombinant K1-3 significantly suppressed endothelial cell proliferation in a dose-dependent manner with an IC50 of 50 nM. Using an animal model of intracranial brain tumors in immune-competent rats, systemic administration of purified recombinant K1-3 resulted in up to 85% suppression of tumor growth (P = 0.011). Growth suppression was accompanied by a 32% decrease (P = 0.01) in tumor neovascularization. This study demonstrates a simple method to produce a biologically active recombinant angiostatin derivative. The ability to suppress intracerebral tumor growth after systemic administration suggests that K1-3 is likely to have therapeutic value in the treatment of malignant glial tumors.</ab>
<no>LR: 20071114; GR: HL42493/HL/NHLBI NIH HHS/United States; GR: HL46403/HL/NHLBI NIH HHS/United States; GR: NS07384/NS/NINDS NIH HHS/United States; GR: etc.; JID: 9502500; 0 (Peptide Fragments); 0 (Recombinant Proteins); 0 (recombinant kringle 1-3 (rKI-3) of human plasminogen); 9001-91-6 (Plasminogen); ppublish</no>
<pp>UNITED STATES</pp>
<sn>1078-0432; 1078-0432</sn>
<ad>Department of Neurosciences, Weill Medical College of Cornell University, New York, New York 10021, USA.</ad>
<an>PMID: 10589788</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>10589788</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1814</id>
<a1>Meneses,P. I.</a1>
<a1>Hajjar,K. A.</a1>
<a1>Berns,K. I.</a1>
<a1>Duvoisin,R. M.</a1>
<t1>Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model</t1>
<jf>Gene therapy</jf>
<jo>Gene Ther.</jo>
<yr>2001</yr>
<fd>Apr</fd>
<vo>8</vo>
<is>8</is>
<sp>646</sp>
<op>648</op>
<k1>Angiostatins</k1>
<k1>Animals</k1>
<k1>Diabetic Retinopathy/prevention &amp; control</k1>
<k1>Disease Models, Animal</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Peptide Fragments/therapeutic use</k1>
<k1>Plasminogen/therapeutic use</k1>
<k1>Recombinant Proteins/therapeutic use</k1>
<k1>Retinal Neovascularization/pathology/prevention &amp; control</k1>
<k1>Transfection</k1>
<ab>Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neovascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovascular retinopathies such as diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion and, possibly, age-related macular degeneration.</ab>
<no>LR: 20071114; GR: AI22251/AI/NIAID NIH HHS/United States; GR: EY09534/EY/NEI NIH HHS/United States; GR: EY13101/EY/NEI NIH HHS/United States; JID: 9421525; 0 (Peptide Fragments); 0 (Recombinant Proteins); 86090-08-6 (Angiostatins); 9001-91-6 (Plasminogen); 2000/09/30 [received]; 2000/12/20 [accepted]; ppublish</no>
<pp>England</pp>
<sn>0969-7128; 0969-7128</sn>
<ad>Department of Microbiology, Weill Medical College of Cornell University, New York, NY, USA.</ad>
<an>PMID: 11320411</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1038/sj.gt.3301423</do>
<ol>Unknown(0)</ol>
<pmid>11320411</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1810</id>
<a1>Mori,K.</a1>
<a1>Gehlbach,P.</a1>
<a1>Yamamoto,S.</a1>
<a1>Duh,E.</a1>
<a1>Zack,D. J.</a1>
<a1>Li,Q.</a1>
<a1>Berns,K. I.</a1>
<a1>Raisler,B. J.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Campochiaro,P. A.</a1>
<t1>AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization</t1>
<jf>Investigative ophthalmology &amp; visual science</jf>
<jo>Invest.Ophthalmol.Vis.Sci.</jo>
<yr>2002</yr>
<fd>Jun</fd>
<vo>43</vo>
<is>6</is>
<sp>1994</sp>
<op>2000</op>
<k1>Animals</k1>
<k1>Choroidal Neovascularization/metabolism/prevention &amp; control</k1>
<k1>Dependovirus/genetics</k1>
<k1>Disease Models, Animal</k1>
<k1>Enzyme-Linked Immunosorbent Assay</k1>
<k1>Eye Proteins/genetics/metabolism</k1>
<k1>Gene Expression</k1>
<k1>Gene Therapy</k1>
<k1>Gene Transfer Techniques</k1>
<k1>Genetic Vectors</k1>
<k1>Green Fluorescent Proteins</k1>
<k1>Injections</k1>
<k1>Luminescent Proteins/genetics/metabolism</k1>
<k1>Male</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Microscopy, Fluorescence</k1>
<k1>Nerve Growth Factors</k1>
<k1>Proteins/genetics/metabolism</k1>
<k1>Serpins/genetics/metabolism</k1>
<k1>Transgenes</k1>
<ab>PURPOSE: Adeno-associated viral (AAV) vectors have been used to express several different proteins in the eye. The purpose of this study was to determine whether AAV-mediated intraocular gene transfer of pigment epithelium-derived factor (PEDF) inhibits the development of choroidal neovascularization (CNV) in a murine model. METHODS: C57BL/6 mice were given intravitreous or subretinal injections of a PEDF expression construct packaged in an AAV vector (AAV-chicken beta-actin promoter-exon 1-intron 1[CBA]-PEDF) or control vector (AAV-CBA-green fluorescent protein[GFP]). After 4 or 6 weeks, the Bruch&amp;#39;s membrane was ruptured by laser photocoagulation at three sites in each eye. After 14 days, the area of CNV at each rupture site was measured by image analysis. Intraocular levels of PEDF were measured by enzyme-linked immunosorbent assay. RESULTS: Four to six weeks after intraocular injection of AAV-CBA-PEDF, levels of PEDF in whole-eye homogenates were 6 to 70 ng. The average area of CNV at sites of the Bruch&amp;#39;s membrane rupture showed no significant difference in eyes injected with AAV-CBA-PEDF compared with uninjected eyes. In contrast, 4 to 6 weeks after intraocular injection of 1.5 x 10(9) or 2.0 x 10(10) particles of AAV-CBA-PEDF, the area of CNV at the Bruch&amp;#39;s membrane rupture sites had significantly decreased compared with CNV area at rupture sites in eyes injected with AAV-CBA-GFP. CONCLUSIONS: These data suggest that intraocular expression of PEDF or other antiangiogenic proteins with AAV vectors may provide a new treatment approach for ocular neovascularization.</ab>
<no>LR: 20071114; GR: EY05951/EY/NEI NIH HHS/United States; GR: EY07132/EY/NEI NIH HHS/United States; GR: EY08571/EY/NEI NIH HHS/United States; GR: EY11123/EY/NEI NIH HHS/United States; GR: EY12609/EY/NEI NIH HHS/United States; GR: EY13101/EY/NEI NIH HHS/United States; GR: EY1765/EY/NEI NIH HHS/United States; GR: NS36302/NS/NINDS NIH HHS/United States; JID: 7703701; 0 (Eye Proteins); 0 (Luminescent Proteins); 0 (Nerve Growth Factors); 0 (Proteins); 0 (Serpins); 0 (pigment epithelium-derived factor); 147336-22-9 (Green Fluorescent Proteins); ppublish</no>
<pp>United States</pp>
<sn>0146-0404; 0146-0404</sn>
<ad>Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA.</ad>
<an>PMID: 12037010</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>12037010</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1866</id>
<a1>Muzyczka,N.</a1>
<a1>Samulski,R. J.</a1>
<a1>Hermonat,P.</a1>
<a1>Srivastava,A.</a1>
<a1>Berns,K. I.</a1>
<t1>The genetics of adeno-associated virus</t1>
<jf>Advances in Experimental Medicine and Biology</jf>
<jo>Adv.Exp.Med.Biol.</jo>
<yr>1984</yr>
<vo>179</vo>
<sp>151</sp>
<op>161</op>
<k1>DNA Replication</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics/metabolism</k1>
<k1>Genes, Viral</k1>
<k1>Mutation</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Virus Replication</k1>
<no>LR: 20061115; JID: 0121103; 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0065-2598; 0065-2598</sn>
<an>PMID: 6098150</an>
<la>eng</la>
<sf>Comparative Study; Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6098150</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1874</id>
<a1>Ostrove,J. M.</a1>
<a1>Berns,K. I.</a1>
<t1>Adenovirus early region 1b gene function required for rescue of latent adeno-associated virus</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1980</yr>
<fd>Jul 30</fd>
<vo>104</vo>
<is>2</is>
<sp>502</sp>
<op>505</op>
<k1>Adenoviridae/genetics/physiology</k1>
<k1>Cell Line</k1>
<k1>DNA Replication</k1>
<k1>Dependovirus/physiology</k1>
<k1>Genes, Viral</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Mutation</k1>
<k1>Temperature</k1>
<k1>Virus Replication</k1>
<no>LR: 20061115; JID: 0110674; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 6249041</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6249041</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1872</id>
<a1>Ostrove,J. M.</a1>
<a1>Duckworth,D. H.</a1>
<a1>Berns,K. I.</a1>
<t1>Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1981</yr>
<fd>Sep</fd>
<vo>113</vo>
<is>2</is>
<sp>521</sp>
<op>533</op>
<k1>Adenoviruses, Human/immunology/physiology</k1>
<k1>Animals</k1>
<k1>Antigens, Neoplasm/analysis</k1>
<k1>Antigens, Viral/analysis</k1>
<k1>Antigens, Viral, Tumor</k1>
<k1>Cell Division</k1>
<k1>Cell Line</k1>
<k1>Cell Transformation, Neoplastic</k1>
<k1>Cell Transformation, Viral</k1>
<k1>Cricetinae</k1>
<k1>Dependovirus/physiology</k1>
<k1>Neoplasms, Experimental/etiology</k1>
<k1>Transcription, Genetic</k1>
<k1>Virus Replication</k1>
<no>LR: 20071114; GR: 1 RO1 AI16326/AI/NIAID NIH HHS/United States; GR: 1T32 AI07110/AI/NIAID NIH HHS/United States; JID: 0110674; 0 (Antigens, Neoplasm); 0 (Antigens, Viral); 0 (Antigens, Viral, Tumor); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<an>PMID: 6267797; 0042-6822(81)90180-X [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6267797</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1811</id>
<a1>Philpott,N. J.</a1>
<a1>Giraud-Wali,C.</a1>
<a1>Dupuis,C.</a1>
<a1>Gomos,J.</a1>
<a1>Hamilton,H.</a1>
<a1>Berns,K. I.</a1>
<a1>Falck-Pedersen,E.</a1>
<t1>Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>2002</yr>
<fd>Jun</fd>
<vo>76</vo>
<is>11</is>
<sp>5411</sp>
<op>5421</op>
<k1>Adenoviruses, Human/genetics</k1>
<k1>DNA, Viral</k1>
<k1>DNA-Binding Proteins/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Gene Expression</k1>
<k1>Gene Transfer Techniques</k1>
<k1>Genetic Vectors/genetics</k1>
<k1>Humans</k1>
<k1>Plasmids</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Recombination, Genetic</k1>
<k1>Viral Proteins/genetics</k1>
<ab>The initial aim of this study was to combine attributes of adeno-associated virus (AAV) and adenovirus (Ad) gene therapy vectors to generate an Ad-AAV hybrid vector allowing efficient site-specific integration with Ad vectors. In executing our experimental strategy, we found that, in addition to the known incompatibility of Rep expression and Ad growth, an equally large obstacle was presented by the inefficiency of the integration event when using traditional recombinant AAV (rAAV) vectors. This study has addressed both of these problems. We have shown that a first-generation Ad can be generated that expresses Rep proteins at levels consistent with those found in wild-type AAV (wtAAV) infections and that Rep-mediated AAV persistence can occur in the presence of first-generation Ad vectors. Our finding that traditional rAAV plasmid vectors lack integration potency compared to wtAAV plasmid constructs (10- to 100-fold differences) was unexpected but led to the discovery of a previously unidentified AAV integration enhancer sequence element which functions in cis to an AAV inverted terminal repeat-flanked target gene. rAAV constructs containing left-end AAV sequence, including the p5-rep promoter sequence, integrate efficiently in a site-specific manner. The identification of this novel AAV integration enhancer element is consistent with previous studies, which have indicated that a high frequency of wtAAV recombinant junction formation occurs in the vicinity of the p5 promoter, and recent studies have demonstrated a role for this region in AAV DNA replication. Understanding the contribution of this element to the mechanism of AAV integration will be critical to the use of AAV vectors for targeted gene transfer applications.</ab>
<no>LR: 20091118; GR: P50 HL59312/HL/NHLBI NIH HHS/United States; JID: 0113724; 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Viral Proteins); 137750-19-7 (rep proteins, Adeno-associated virus 2); OID: NLM: PMC137060; ppublish</no>
<pp>United States</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Molecular Biology Graduate Program, Hearst Research Foundation, Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.</ad>
<an>PMID: 11991970</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>11991970</pmid>
<pmcid>PMC137060</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1808</id>
<a1>Philpott,N. J.</a1>
<a1>Gomos,J.</a1>
<a1>Berns,K. I.</a1>
<a1>Falck-Pedersen,E.</a1>
<t1>A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>2002</yr>
<fd>Sep 17</fd>
<vo>99</vo>
<is>19</is>
<sp>12381</sp>
<op>12385</op>
<k1>Base Sequence</k1>
<k1>Binding Sites/genetics</k1>
<k1>Chromosomes, Human, Pair 19/genetics/virology</k1>
<k1>DNA, Viral/genetics/metabolism</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Molecular Sequence Data</k1>
<k1>Plasmids/genetics</k1>
<k1>Promoter Regions, Genetic</k1>
<k1>Viral Proteins/metabolism</k1>
<k1>Virus Integration/genetics</k1>
<ab>Adeno-associated virus (AAV) undergoes site-specific integration into human chromosome 19 through a deletion-substitution mechanism at the well characterized AAVS1 site. We have shown previously that a cis element within the left end of the AAV genome enhances the efficiency of Rep-mediated site-specific integration into chromosome 19 when present in inverted terminal repeat-containing recombinant AAV (rAAV) plasmids. We now demonstrate that a 138-bp cis element, the p5 integration efficiency element (p5IEE), mediates efficient integration. The p5IEE is not only required for efficient site-specific integration, it is also sufficient. Integration mediated by the p5IEE occurs in the absence of the AAV inverted terminal-repeat elements. The data presented in this study demonstrate that the p5IEE is a multifunctional element, serving as the highly regulatable Rep promoter and the primary substrate for targeted integration.</ab>
<no>LR: 20091118; GR: EY13101/EY/NEI NIH HHS/United States; GR: P50 HL59312/HL/NHLBI NIH HHS/United States; JID: 7505876; 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Viral Proteins); 137750-19-7 (rep proteins, Adeno-associated virus 2); OID: NLM: PMC129453; 2002/09/09 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Weill Medical College of Cornell University, Hearst Research Foundation Department of Microbiology and Immunology, Molecular Biology Graduate Program, New York, NY 10021, USA.</ad>
<an>PMID: 12221283; 182430299 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1073/pnas.182430299</do>
<wp>20020909</wp>
<ol>Unknown(0)</ol>
<pmid>12221283</pmid>
<pmcid>PMC129453</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1809</id>
<a1>Raisler,B. J.</a1>
<a1>Berns,K. I.</a1>
<a1>Grant,M. B.</a1>
<a1>Beliaev,D.</a1>
<a1>Hauswirth,W. W.</a1>
<t1>Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>2002</yr>
<fd>Jun 25</fd>
<vo>99</vo>
<is>13</is>
<sp>8909</sp>
<op>8914</op>
<k1>Angiostatins</k1>
<k1>Animals</k1>
<k1>Dependovirus/genetics</k1>
<k1>Disease Models, Animal</k1>
<k1>Enzyme-Linked Immunosorbent Assay</k1>
<k1>Eye Proteins</k1>
<k1>Genetic Vectors</k1>
<k1>Kringles/genetics</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Neovascularization, Pathologic/genetics</k1>
<k1>Nerve Growth Factors</k1>
<k1>Peptide Fragments/chemistry/genetics</k1>
<k1>Plasminogen/chemistry/genetics</k1>
<k1>Proteins/genetics</k1>
<k1>Retinal Vessels/growth &amp; development</k1>
<k1>Serpins/genetics</k1>
<ab>Neovascular diseases of the retina include age-related macular degeneration and diabetic retinopathy, and together they comprise the leading causes of adult-onset blindness in developed countries. Current surgical, pharmaceutical, and laser therapies for age-related macular degeneration (AMD) rarely result in improved vision, do not significantly prevent neovascularization (NV), and often result in at least some vision loss. To address this therapeutic gap, we determined the efficacy of recombinant adeno-associated viral (rAAV) serotype-2-mediated expression of pigment epithelium-derived factor (PEDF) or Kringle domains 1-3 of angiostatin (K1K3) in reducing aberrant vessel formation in a mouse model of ischemia-induced retinal NV. Both PEDF and K1K3 are potent inhibitors of NV when injected directly, hence expression of these therapeutic factors from rAAV may provide long-term protection from neovascular eye disease. rAAV vectors expressing the therapeutic gene were injected into one eye of postnatal day 0 (P0) newborn mouse pups. Retinal NV was induced in P7 mice by exposure to elevated oxygen for 5 days followed by room air for another five days. Retinal NV was quantified by the number of vascular-endothelial-cell nuclei above the inner-limiting membrane in P17 eyes. The number of such vascular endothelial cell nuclei in eyes treated with rAAV-PEDF or rAAV-K1K3 was significantly reduced (both P &amp;lt; 0.0000002) compared with control eyes. Ocular protein levels detected by ELISA correlate well with the reduction in NV and confirm that expression of antineovascular agents from rAAV vectors may be a therapeutically useful treatment of retinal or choroidal neovascular disease.</ab>
<no>LR: 20091118; GR: EY11123/EY/NEI NIH HHS/United States; GR: EY13729/EY/NEI NIH HHS/United States; GR: NS36302/NS/NINDS NIH HHS/United States; GR: T32EY07043/EY/NEI NIH HHS/United States; JID: 7505876; 0 (Eye Proteins); 0 (Nerve Growth Factors); 0 (Peptide Fragments); 0 (Proteins); 0 (Serpins); 0 (pigment epithelium-derived factor); 86090-08-6 (Angiostatins); 9001-91-6 (Plasminogen); OID: NLM: PMC124397; 2002/06/18 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Ophthalmology, Box 100284, University of Florida, Gainesville, FL 32610-0284, USA.</ad>
<an>PMID: 12072560; 122247299 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1073/pnas.122247299</do>
<wp>20020618</wp>
<ol>Unknown(0)</ol>
<pmid>12072560</pmid>
<pmcid>PMC124397</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1826</id>
<a1>Ralston,H. J.,3rd</a1>
<a1>Beattie,D. S.</a1>
<a1>Berns,K. I.</a1>
<a1>Goode,L. D.</a1>
<a1>Kelley,W. N.</a1>
<a1>Lennarz,W. J.</a1>
<a1>Marton,L. J.</a1>
<a1>Prange,A. J.,Jr</a1>
<a1>Shipp,A. C.</a1>
<t1>Capturing the promise of science in medical schools</t1>
<jf>Academic medicine : journal of the Association of American Medical Colleges</jf>
<jo>Acad.Med.</jo>
<yr>1996</yr>
<fd>Dec</fd>
<vo>71</vo>
<is>12</is>
<sp>1314</sp>
<op>1323</op>
<k1>Diffusion of Innovation</k1>
<k1>Education, Medical</k1>
<k1>Ethics, Medical</k1>
<k1>Industry</k1>
<k1>Interinstitutional Relations</k1>
<k1>Research</k1>
<k1>Research Support as Topic</k1>
<k1>Schools, Medical/organization &amp; administration</k1>
<k1>United States</k1>
<k1>Universities</k1>
<ab>To gain a better understanding of the effects on medical schools of transformations in medical practice, science, and public expectations, the Association of American Medical Colleges (AAMC) constituted the Advisory Panel on the Mission and Organization of Medical Schools (APMOMS) in 1994. APMOMS created six working groups to address the issues deemed by panel members to be of highest priority. This article is a report of the findings of the Working Group on Capturing the Promise of Medical Research, which addressed questions concerning the direction of research and the integration of scientific developments in medical education and practice. The working group explored a broad panorama of issues, including those related to sustaining the accomplishments, momentum, and progress of medical research. A dominant theme emerged: the central importance of an environment of discovery to the core missions of medical schools. The present article consists of the group&amp;#39;s comments and recommendations on the main topic-the promise of biomedical research in relation to medical education-and their comments and recommendations on five other topics that have important relationships to the main topic and to the group&amp;#39;s central charge. These are ethics; academia-industry relations; the administrative structure of medical schools; university-medical school relations; and research funding.</ab>
<no>LR: 20071115; JID: 8904605; ppublish</no>
<pp>UNITED STATES</pp>
<sn>1040-2446; 1040-2446</sn>
<ad>Department of Anatomy, University of California, School of Medicine, San Francisco, USA.</ad>
<an>PMID: 9114889</an>
<la>eng</la>
<sf>Journal Article; AIM; IM</sf>
<ol>Unknown(0)</ol>
<pmid>9114889</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1865</id>
<a1>Rand,K. H.</a1>
<a1>Berns,K. I.</a1>
<a1>Rayfield,M. A.</a1>
<t1>Recovery of herpes simplex type 1 from the celiac ganglion after renal transplantation</t1>
<jf>Southern medical journal</jf>
<jo>South.Med.J.</jo>
<yr>1984</yr>
<fd>Mar</fd>
<vo>77</vo>
<is>3</is>
<sp>403</sp>
<op>404</op>
<k1>Esophagitis/microbiology</k1>
<k1>Ganglia, Sympathetic/microbiology</k1>
<k1>Herpes Simplex/complications</k1>
<k1>Humans</k1>
<k1>Kidney Transplantation</k1>
<k1>Male</k1>
<k1>Middle Aged</k1>
<k1>Peptic Ulcer/complications</k1>
<k1>Simplexvirus/isolation &amp; purification</k1>
<ab>Herpes simplex type 1 was recovered from the celiac ganglion of a renal transplant patient who had esophageal lesions consistent with herpes simplex esophagitis as well as peptic ulcers requiring operation. We speculate that the virus got to the celiac ganglion via retrograde spread from the stomach and/or duodenum. Further studies are needed to determine the frequency of HSV involvement in visceral autonomic ganglia and whether by reactivation it could lead to subsequent gastrointestinal ulceration.</ab>
<no>LR: 20071114; GR: 1-R01-AI-16326-01/AI/NIAID NIH HHS/United States; JID: 0404522; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0038-4348; 0038-4348</sn>
<an>PMID: 6322356</an>
<la>eng</la>
<sf>Case Reports; Journal Article; Research Support, U.S. Gov&#39;t, Non-P.H.S.; Research Support, U.S. Gov&#39;t, P.H.S.; AIM; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6322356</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1893</id>
<a1>Rose,J. A.</a1>
<a1>Berns,K. I.</a1>
<a1>Hoggan,M. D.</a1>
<a1>Koczot,F. J.</a1>
<t1>Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>1969</yr>
<fd>Nov</fd>
<vo>64</vo>
<is>3</is>
<sp>863</sp>
<op>869</op>
<k1>Adenoviridae</k1>
<k1>Bromodeoxyuridine</k1>
<k1>Centrifugation, Density Gradient</k1>
<k1>Centrifugation, Zonal</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Hybridization, Genetic</k1>
<k1>Satellite Viruses</k1>
<k1>Specific Gravity</k1>
<ab>Extracted adenovirus-associated virus DNA is known to be double-stranded, and, therefore, it has been assumed that these virus particles contain a double-stranded genome. Recent findings, however, have suggested that the DNA in virus particles is equivalent to only half the molecular weight of extracted molecules. A density analysis of DNA extracted from a mixture of virus particles containing either bromodeoxyuridine-substituted or unsubstituted DNA shows that virions contain single-stranded DNA which, when released, forms duplex structures. A similar circumstance is as yet unknown among other viruses.</ab>
<no>LR: 20091118; JID: 7505876; 0 (DNA, Viral); 59-14-3 (Bromodeoxyuridine); OID: NLM: PMC223314; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0027-8424; 0027-8424</sn>
<an>PMID: 5264145</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>5264145</pmid>
<pmcid>PMC223314</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1867</id>
<a1>Samulski,R. J.</a1>
<a1>Srivastava,A.</a1>
<a1>Berns,K. I.</a1>
<a1>Muzyczka,N.</a1>
<t1>Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV</t1>
<jf>Cell</jf>
<jo>Cell</jo>
<yr>1983</yr>
<fd>May</fd>
<vo>33</vo>
<is>1</is>
<sp>135</sp>
<op>143</op>
<k1>Chromosome Deletion</k1>
<k1>DNA Replication</k1>
<k1>DNA Transposable Elements</k1>
<k1>DNA, Recombinant</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Defective Viruses/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Humans</k1>
<k1>Mutation</k1>
<k1>Plasmids</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Virus Replication</k1>
<ab>We have isolated three types of pBR322-AAV recombinant plasmids that contain deletions within the 145 bp AAV terminal repeats. When the plasmids were transfected into human cells, mutants that contained deletions within the left (type I) or right (type II) terminal repeat were viable. Of four mutants examined that contained deletions in both termini (type III), only one was viable. All of the viable mutants produced AAV virions that contained wild-type AAV DNA. Furthermore, the viable type III deletion could be converted to a nonviable mutant by deleting all copies of an 11 bp sequence from its termini. We conclude that there is an efficient mechanism for correcting deletions within the AAV termini. A model that could account for these observations is also discussed.</ab>
<no>LR: 20071114; GENBANK/J01901; GENBANK/M12405; GENBANK/M12468; GENBANK/M12469; GR: 5 R01 AI16326/AI/NIAID NIH HHS/United States; GR: 5 T32 AI07110/AI/NIAID NIH HHS/United States; JID: 0413066; 0 (DNA Transposable Elements); 0 (DNA, Recombinant); 0 (DNA, Viral); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0092-8674; 0092-8674</sn>
<an>PMID: 6088052; 0092-8674(83)90342-2 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6088052</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1860</id>
<a1>Siegl,G.</a1>
<a1>Bates,R. C.</a1>
<a1>Berns,K. I.</a1>
<a1>Carter,B. J.</a1>
<a1>Kelly,D. C.</a1>
<a1>Kurstak,E.</a1>
<a1>Tattersall,P.</a1>
<t1>Characteristics and taxonomy of Parvoviridae</t1>
<jf>Intervirology</jf>
<jo>Intervirology</jo>
<yr>1985</yr>
<vo>23</vo>
<is>2</is>
<sp>61</sp>
<op>73</op>
<k1>Base Sequence</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Genes, Viral</k1>
<k1>Parvoviridae/classification/genetics</k1>
<no>LR: 20001218; JID: 0364265; 0 (DNA, Viral); ppublish</no>
<pp>SWITZERLAND</pp>
<sn>0300-5526; 0300-5526</sn>
<an>PMID: 3980186</an>
<la>eng</la>
<sf>Journal Article; IM</sf>
<ol>Unknown(0)</ol>
<pmid>3980186</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1869</id>
<a1>Slilaty,S. N.</a1>
<a1>Berns,K. I.</a1>
<a1>Aposhian,H. V.</a1>
<t1>Polyoma-like particle: characterization of the DNA encapsidated in vitro by polyoma empty capsids</t1>
<jf>The Journal of biological chemistry</jf>
<jo>J.Biol.Chem.</jo>
<yr>1982</yr>
<fd>Jun 10</fd>
<vo>257</vo>
<is>11</is>
<sp>6571</sp>
<op>6575</op>
<k1>Capsid/metabolism</k1>
<k1>DNA Restriction Enzymes</k1>
<k1>DNA, Circular/metabolism</k1>
<k1>DNA, Superhelical/metabolism</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>Molecular Weight</k1>
<k1>Nucleic Acid Conformation</k1>
<k1>Nucleic Acid Hybridization</k1>
<k1>Polydeoxyribonucleotides/metabolism</k1>
<k1>Polyomavirus/metabolism</k1>
<k1>Viral Proteins/metabolism</k1>
<ab>Polyoma empty capsids and DNA interact in a cell-free system to form a polyoma-like particle (PLP). The particle is stable in high concentrations of salt and contains a DNA fragment that is protected by the capsid from the action of DNase I. The DNA extracted from PLP is heterogeneous in size. It has a mean molecular weight of 1.2 x 10(6) with a standard deviation of +/- 0.5 x 10(6). Analysis of PLP DNA with restriction endonucleases and the Southern blot technique reveals that a specific primary sequence is not required for PLP formation. Either linear, circular, or supercoiled polyoma DNA, as well as single-stranded DNA, rRNA, and the synthetic homopolymers poly(dA) . poly(dT) and poly(dG) . poly(dC) can be used for PLP formation. It is concluded that polyoma empty capsids can be used to bind and encapsidate nucleic acids differing in their primary, secondary, and superhelical tertiary structure to form, in vitro, stable polyoma-like particles.</ab>
<no>LR: 20061115; JID: 2985121R; 0 (DNA, Circular); 0 (DNA, Superhelical); 0 (DNA, Viral); 0 (Polydeoxyribonucleotides); 0 (Viral Proteins); EC 3.1.21.- (DNA Restriction Enzymes); ppublish</no>
<pp>UNITED STATES</pp>
<sn>0021-9258; 0021-9258</sn>
<an>PMID: 6281277</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, Non-P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6281277</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1812</id>
<a1>Song,S.</a1>
<a1>Embury,J.</a1>
<a1>Laipis,P. J.</a1>
<a1>Berns,K. I.</a1>
<a1>Crawford,J. M.</a1>
<a1>Flotte,T. R.</a1>
<t1>Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors</t1>
<jf>Gene therapy</jf>
<jo>Gene Ther.</jo>
<yr>2001</yr>
<fd>Sep</fd>
<vo>8</vo>
<is>17</is>
<sp>1299</sp>
<op>1306</op>
<k1>Animals</k1>
<k1>Blotting, Southern</k1>
<k1>Dependovirus/genetics</k1>
<k1>Female</k1>
<k1>Gene Expression</k1>
<k1>Gene Therapy/methods</k1>
<k1>Genetic Vectors/administration &amp; dosage</k1>
<k1>Humans</k1>
<k1>Injections, Intravenous</k1>
<k1>Liver/metabolism</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Models, Animal</k1>
<k1>Portal Vein</k1>
<k1>Transgenes</k1>
<k1>alpha 1-Antitrypsin/genetics/metabolism</k1>
<ab>Previous work from our group showed that recombinant adeno-associated virus (rAAV) vectors mediated long-term secretion of therapeutic serum levels of human alpha-1 antitrypsin (hAAT) after a single injection in murine muscle. We hypothesized that hepatocyte transduction could be even more efficient, since these cells represent the natural site of AAT production and secretion. To test this hypothesis, rAAV vectors containing the hAAT cDNA driven by either the human elongation factor 1 alpha promoter, the human cytomegalovirus immediate-early promoter (CMV), or the CMV-chicken beta actin hybrid (CB) promoter were injected into the portal or tail veins of adult C57Bl/6 mice. Potentially therapeutic serum levels of hAAT (600 microg/ml) were achieved after portal vein injection of doses of 4 x 10(9) infectious units (IU), a 10-fold lower dose than that required for similar levels of expression via the i.m. route. Serum levels greater than 1 mg/ml were achieved at doses of 3 x 10(10) IU. Southern blotting of liver DNA revealed the presence of circular episomal vector genomes. Immunostaining showed that transgene expression was scattered throughout the liver parenchyma. Similar results were obtained with a rAAV-CB-green fluorescent protein (GFP) vector. There was no evidence of hepatic toxicity. These data indicate that liver-directed rAAV-based gene therapy is effective in the murine model, and hence might be feasible for treatment of human AAT deficiency.</ab>
<no>LR: 20071114; GR: P01-HL-51811/HL/NHLBI NIH HHS/United States; GR: P021-DK-58327/DK/NIDDK NIH HHS/United States; GR: P50-HL-59412/HL/NHLBI NIH HHS/United States; GR: R01-DK-51809/DK/NIDDK NIH HHS/United States; GR: R01-DK-53512/DK/NIDDK NIH HHS/United States; JID: 9421525; 0 (alpha 1-Antitrypsin); 2000/09/22 [received]; 2000/12/21 [accepted]; ppublish</no>
<pp>England</pp>
<sn>0969-7128; 0969-7128</sn>
<ad>Department of Pediatrics, University of Florida Genetics Institute, Gainesville, FL 32610-0266, USA.</ad>
<an>PMID: 11571566</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1038/sj.gt.3301422</do>
<ol>Unknown(0)</ol>
<pmid>11571566</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1815</id>
<a1>Song,S.</a1>
<a1>Laipis,P. J.</a1>
<a1>Berns,K. I.</a1>
<a1>Flotte,T. R.</a1>
<t1>Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>2001</yr>
<fd>Mar 27</fd>
<vo>98</vo>
<is>7</is>
<sp>4084</sp>
<op>4088</op>
<k1>Animals</k1>
<k1>DNA-Activated Protein Kinase</k1>
<k1>DNA-Binding Proteins</k1>
<k1>Dependovirus/drug effects/genetics</k1>
<k1>Genetic Vectors</k1>
<k1>Genome, Viral</k1>
<k1>Mice</k1>
<k1>Mice, Inbred C57BL</k1>
<k1>Mice, SCID</k1>
<k1>Muscle, Skeletal/drug effects/physiology/virology</k1>
<k1>Protein-Serine-Threonine Kinases/pharmacology</k1>
<ab>We report here that the DNA-dependent protein kinase (DNA-PK) affects the molecular fate of the recombinant adeno-associated virus (rAAV) genome in skeletal muscle. rAAV-human alpha1-antitrypsin (rAAV-hAAT) vectors were delivered by intramuscular injection to either C57BL/6 (DNA-PKcs(+)) or C57BL/6-SCID [severe combined immunodeficient (SCID), DNA-PKcs(-)] mice. In both strains, high levels of transgene expression were sustained for up to 1 year after a single injection. Southern blot analysis showed that rAAV genomes persisted as linear episomes for more than 1 year in SCID mice, whereas only circular episomal forms were observed in the C57BL/6 strain. These results indicate that DNA-PK is involved in the formation of circular rAAV episomes.</ab>
<no>LR: 20091119; GR: DK51809/DK/NIDDK NIH HHS/United States; GR: DK58237/DK/NIDDK NIH HHS/United States; GR: GM50032/GM/NIGMS NIH HHS/United States; GR: HL51811/HL/NHLBI NIH HHS/United States; GR: HL59412/HL/NHLBI NIH HHS/United States; JID: 7505876; 0 (DNA-Binding Proteins); EC 2.7.11.1 (DNA-Activated Protein Kinase); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); OID: NLM: PMC31183; 2001/03/13 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Genetics Institute, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA.</ad>
<an>PMID: 11274433; 061014598 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1073/pnas.061014598</do>
<wp>20010313</wp>
<ol>Unknown(0)</ol>
<pmid>11274433</pmid>
<pmcid>PMC31183</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1805</id>
<a1>Song,S.</a1>
<a1>Lu,Y.</a1>
<a1>Choi,Y. K.</a1>
<a1>Han,Y.</a1>
<a1>Tang,Q.</a1>
<a1>Zhao,G.</a1>
<a1>Berns,K. I.</a1>
<a1>Flotte,T. R.</a1>
<t1>DNA-dependent PK inhibits adeno-associated virus DNA integration</t1>
<jf>Proceedings of the National Academy of Sciences of the United States of America</jf>
<jo>Proc.Natl.Acad.Sci.U.S.A.</jo>
<yr>2004</yr>
<fd>Feb 17</fd>
<vo>101</vo>
<is>7</is>
<sp>2112</sp>
<op>2116</op>
<k1>Animals</k1>
<k1>Cell Line</k1>
<k1>DNA, Viral/genetics</k1>
<k1>DNA-Activated Protein Kinase</k1>
<k1>DNA-Binding Proteins</k1>
<k1>Dependovirus/genetics/physiology</k1>
<k1>Genome, Viral</k1>
<k1>Hepatectomy</k1>
<k1>Humans</k1>
<k1>Liver/virology</k1>
<k1>Male</k1>
<k1>Mice</k1>
<k1>Nuclear Proteins</k1>
<k1>Protein-Serine-Threonine Kinases/antagonists &amp; inhibitors/genetics/metabolism</k1>
<k1>Recombination, Genetic/genetics</k1>
<k1>Virus Integration</k1>
<ab>Recent studies have shown that recombinant adeno-associated virus (rAAV) can persist in episomal form; however, factors affecting rAAV persistence are poorly understood. DNA-dependent PK (DNA-PK) is a DNA repair enzyme, which we previously found played an important role in determining the molecular fate of the rAAV genome in mouse skeletal muscle. In the present study, we tested the effect of DNA-PK on AAV serotype 2 integration in vitro and in vivo in mouse liver. In an in vitro integration system, addition of DNA-PK decreased AAV integration, whereas antibody against DNA-PKcs increased integration. In vivo, matched doses of a recombinant AAV serotype 2 vector were injected into the portal vein of either C57BL/6 (DNA-PKcs(+/+)) or severe combined immunodeficient (DNA-PKcs(-/-)) mice. After partial hepatectomy to stimulate hepatocyte proliferation, retention of vector genomes and of transgene expression was substantially higher in severe combined immunodeficient mice, indicating that in the absence of DNA-PKcs, a greater proportion of genomes integrated into the cellular genome. In summary, we have provided evidence that DNA-PK inhibits AAV integration both in vitro and in vivo.</ab>
<no>LR: 20091119; GR: DK58327/DK/NIDDK NIH HHS/United States; GR: DK62652/DK/NIDDK NIH HHS/United States; GR: HL59412/HL/NHLBI NIH HHS/United States; GR: HL69877/HL/NHLBI NIH HHS/United States; JID: 7505876; 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Nuclear Proteins); EC 2.7.1.37 (PRKDC protein, human); EC 2.7.11.1 (DNA-Activated Protein Kinase); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); OID: NLM: PMC357060; 2004/02/06 [aheadofprint]; ppublish</no>
<pp>United States</pp>
<sn>0027-8424; 0027-8424</sn>
<ad>Department of Pharmaceutics, Powell Gene Therapy Center, Genetics Institute, University of Florida, Gainesville, FL 32610, USA. shsong@ufl.edu</ad>
<an>PMID: 14766968; 0307833100 [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1073/pnas.0307833100</do>
<wp>20040206</wp>
<ol>Unknown(0)</ol>
<pmid>14766968</pmid>
<pmcid>PMC357060</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1880</id>
<a1>Spear,I. S.</a1>
<a1>Fife,K. H.</a1>
<a1>Hauswirth,W. W.</a1>
<a1>Jones,C. J.</a1>
<a1>Berns,K. I.</a1>
<t1>Evidence for two nucleotide sequence orientations within the terminal repetition of adeno-associated virus DNA</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1977</yr>
<fd>Nov</fd>
<vo>24</vo>
<is>2</is>
<sp>627</sp>
<op>634</op>
<k1>Base Sequence</k1>
<k1>DNA Restriction Enzymes</k1>
<k1>DNA, Viral/analysis</k1>
<k1>Models, Biological</k1>
<k1>Parvoviridae/analysis</k1>
<k1>Satellite Viruses/analysis</k1>
<ab>Duplex adeno-associated virus (AAV) DNA, produced by annealing plus and minus virion single strands, has been digested with several bacterial restriction endonucleases. These studies reveal the existence of alternate secondary structures at the termini of duplex AAV DNA. Analysis of the sites of endo R-Hpa II cleavage, the products of complete endo R-Hpa II digestion, and the multiple terminal secondary structures leads to the conclusion that there are two possible nucleotide sequences at each end of AAV DNA. A model that attributes the terminal nucleotide sequence heterogeneity to two possible orientations of the first 120 nucleotides at each end of the DNA is proposed; in one case the sequence is 1 to 120; in the other case the sequence is inverted. An origin of the inversion is suggested based on previously described intermediates in AAV DNA replication.</ab>
<no>LR: 20091118; JID: 0113724; 0 (DNA, Viral); EC 3.1.21.- (DNA Restriction Enzymes); OID: NLM: PMC515974; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 916029</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>916029</pmid>
<pmcid>PMC515974</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1868</id>
<a1>Srivastava,A.</a1>
<a1>Lusby,E. W.</a1>
<a1>Berns,K. I.</a1>
<t1>Nucleotide sequence and organization of the adeno-associated virus 2 genome</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1983</yr>
<fd>Feb</fd>
<vo>45</vo>
<is>2</is>
<sp>555</sp>
<op>564</op>
<k1>Amino Acid Sequence</k1>
<k1>Base Sequence</k1>
<k1>Capsid/genetics</k1>
<k1>Codon</k1>
<k1>DNA, Viral/genetics</k1>
<k1>Dependovirus/genetics</k1>
<k1>Genes, Viral</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Transcription, Genetic</k1>
<ab>The complete nucleotide sequence of the adeno-associated virus 2 genome was determined. The single-stranded genome is 4,675 nucleotides in length and contains inverted terminal repeats of 145 nucleotides, the first 125 nucleotides of which form a palindromic sequence. Within the inverted terminal repetitions, there are two distinct sequences representing an inversion of 43 nucleotides that can exist on either terminus. The 5&amp;#39; and 3&amp;#39; termini of three major mRNA transcripts, which are present in both spliced and unspliced forms, were also mapped on the viral genome. Potential initiation and termination codons for efficient protein synthesis were identified, and genome segments were assigned that code for three major viral capsid proteins and, possibly, some as-yet-unidentified, nonstructural viral proteins.</ab>
<no>LR: 20091118; GENBANK/J01901; GENBANK/M12405; GENBANK/M12468; GENBANK/M12469; GR: R01 AI16326/AI/NIAID NIH HHS/United States; JID: 0113724; 0 (Codon); 0 (DNA, Viral); OID: NLM: PMC256449; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<an>PMID: 6300419</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>6300419</pmid>
<pmcid>PMC256449</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1896</id>
<a1>THOMAS,C. A.,Jr</a1>
<a1>BERNS,K. I.</a1>
<t1>The utility of formaldehyde in stabilizing polynucleotide chains from bacteriophage DNA</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1962</yr>
<fd>Apr</fd>
<vo>4</vo>
<sp>309</sp>
<op>312</op>
<k1>Bacteriophages/chemistry</k1>
<k1>DNA/chemistry</k1>
<k1>Formaldehyde/chemistry</k1>
<k1>Nucleosides/chemistry</k1>
<k1>Nucleotides/chemistry</k1>
<k1>BACTERIOPHAGE/chemistry</k1>
<k1>DESOXYRIBONUCLEIC ACID/chemistry</k1>
<k1>NUCLEOSIDES AND NUCLEOTIDES/chemistry</k1>
<no>LR: 20061115; JID: 2985088R; 0 (Nucleosides); 0 (Nucleotides); 50-00-0 (Formaldehyde); 9007-49-2 (DNA); OTO: NLM; ppublish</no>
<pp>Not Available</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 13920751</an>
<la>eng</la>
<sf>Journal Article; OM</sf>
<ol>Unknown(0)</ol>
<pmid>13920751</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1897</id>
<a1>THOMAS,C. A.,Jr</a1>
<a1>BERNS,K. I.</a1>
<t1>The physical characterization of DNA molecules released from T2 and T4 bacteriophage</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1961</yr>
<fd>Jun</fd>
<vo>3</vo>
<sp>277</sp>
<op>288</op>
<k1>Bacteriophages/metabolism</k1>
<k1>DNA/chemistry</k1>
<k1>Escherichia coli</k1>
<k1>BACTERIOPHAGE/metabolism</k1>
<k1>DESOXYRIBONUCLEIC ACID/chemistry</k1>
<no>LR: 20061115; JID: 2985088R; 9007-49-2 (DNA); OTO: NLM; ppublish</no>
<pp>Not Available</pp>
<sn>0022-2836; 0022-2836</sn>
<an>PMID: 13776441</an>
<la>eng</la>
<sf>Journal Article; OM</sf>
<ol>Unknown(0)</ol>
<pmid>13776441</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1829</id>
<a1>Ward,P.</a1>
<a1>Berns,K. I.</a1>
<t1>In vitro replication of adeno-associated virus DNA: enhancement by extracts from adenovirus-infected HeLa cells</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1996</yr>
<fd>Jul</fd>
<vo>70</vo>
<is>7</is>
<sp>4495</sp>
<op>4501</op>
<k1>Cell Extracts</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>Dependovirus/genetics/metabolism/physiology</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Virus Replication</k1>
<ab>Previously we have described an in vitro assay for the replication of adeno-associated virus type 2 (AAV2) DNA. Addition of the AAV2 nonstructural protein Rep68 to an extract from uninfected cells supports the replication of linear duplex AAV DNA. In this report, we examine replication of linear duplex AAV DNA in extracts from either uninfected or adenovirus (Ad)-infected HeLa cells. The incorporation of radiolabeled nucleotides into full-length linear AAV DNA is 50-fold greater in extracts from Ad-infected cells than in extracts from uninfected cells. In addition, the majority of the labeled full-length AAV DNA molecules synthesized in the Ad-infected extract have two newly replicated strands, whereas the majority of labeled full-length AAV DNA molecules synthesized in the uninfected extract have only one newly replicated strand. The numbers of replication initiations on original templates in the two assays are approximately the same; however, replication in the case of the Ad-infected cell extract is much more likely to result in the synthesis of a full-length AAV DNA molecule. Most of the newly replicated molecules in the assay using uninfected cell extracts are in the form of stem-loop structures. We hypothesize that Ad infection provides a helper function related to elongation during replication by a single-strand displacement mechanism. In the assay using the uninfected HeLa cell extract, replication frequently stalls before reaching the end of the genome, causing the newly synthesized strand to be displaced from the template, with a consequent folding on itself and replication back through the inverted terminal repeat, using itself as a template. In support of this conjecture, replication in the uninfected cell extract of shorter substrate molecules is more efficient, as measured by incorporation of radiolabeled nucleotides into full-length substrate DNA. In addition, when shorter substrate molecules are used as the template in the uninfected HeLa cell assay, a greater proportion of the labeled full-length substrate molecules contain two newly replicated strands. Shorter substrate molecules have no replicative advantage over full-length substrate molecules in the assay using an extract from Ad-infected cells.</ab>
<no>LR: 20091118; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (Cell Extracts); 0 (DNA, Viral); OID: NLM: PMC190384; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA.</ad>
<an>PMID: 8676474</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8676474</pmid>
<pmcid>PMC190384</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1835</id>
<a1>Ward,P.</a1>
<a1>Berns,K. I.</a1>
<t1>Minimum origin requirements for linear duplex AAV DNA replication in vitro</t1>
<jf>Virology</jf>
<jo>Virology</jo>
<yr>1995</yr>
<fd>Jun 1</fd>
<vo>209</vo>
<is>2</is>
<sp>692</sp>
<op>695</op>
<k1>DNA Replication</k1>
<k1>Dependovirus/genetics/metabolism</k1>
<k1>Genome, Viral</k1>
<k1>Models, Genetic</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Replication Origin</k1>
<k1>Restriction Mapping</k1>
<k1>Sequence Deletion</k1>
<k1>Templates, Genetic</k1>
<ab>We have investigated the minimal requirements for a functional origin of DNA replication in an in vitro assay which requires the adeno-associated virus (AAV) Rep 68/78 protein. When a linear duplex template was used, initiation of one round of DNA replication was achieved when nucleotides 1-56 of the AAV inverted terminal repeat (in the flop orientation) were present at the terminus of the template. A terminal resolution site was not required. Deletion of an additional 11 nucleotides from the terminal repeat blocked the reaction.</ab>
<no>LR: 20071114; GR: GM50023/GM/NIGMS NIH HHS/United States; JID: 0110674; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0042-6822; 0042-6822</sn>
<ad>Department of Microbiology, W. R. Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA.</ad>
<an>PMID: 7778304; S0042-6822(85)71306-2 [pii]</an>
<la>eng</la>
<sf>Comparative Study; Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<do>10.1006/viro.1995.1306</do>
<ol>Unknown(0)</ol>
<pmid>7778304</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1846</id>
<a1>Ward,P.</a1>
<a1>Berns,K. I.</a1>
<t1>In vitro rescue of an integrated hybrid adeno-associated virus/simian virus 40 genome</t1>
<jf>Journal of Molecular Biology</jf>
<jo>J.Mol.Biol.</jo>
<yr>1991</yr>
<fd>Apr 20</fd>
<vo>218</vo>
<is>4</is>
<sp>791</sp>
<op>804</op>
<k1>Adenoviruses, Human/genetics/growth &amp; development/immunology</k1>
<k1>Antigens, Viral, Tumor/genetics</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Hydrolysis</k1>
<k1>Linkage (Genetics)</k1>
<k1>Plasmids</k1>
<k1>Recombination, Genetic</k1>
<k1>Repetitive Sequences, Nucleic Acid</k1>
<k1>Simian virus 40/genetics/growth &amp; development/immunology</k1>
<k1>Virus Replication</k1>
<ab>In an in vitro simian virus 40 (SV40) DNA replication assay, we have observed excision of a hybrid adeno-associated virus (AAV)/SV40 insert from a plasmid construct. The excision was dependent on the presence of the palindromic AAV terminal repeat and greatly enhanced by the addition of the SV40 T antigen to the reaction. Analysis of the excision product supports a model in which the palindromic terminal sequences of AAV form a cruciform structure (equivalent to a Holliday recombination intermediate), which is cleaved and resealed so that the excision products are linear duplex pBR322 and linear duplex AAV/SV40 insert. Both the excised linear duplex pBR322 and the excised linear duplex AAV/SV40 insert have each terminus covalently crosslinked by one copy of the palindromic region of the AAV terminal repeat region folded on itself. The excision process may be a model system for cellular homologous recombination. The process as observed was either concomitant with or subsequent to DNA replication.</ab>
<no>LR: 20071114; GR: AI-26122/AI/NIAID NIH HHS/United States; JID: 2985088R; 0 (Antigens, Viral, Tumor); ppublish</no>
<pp>ENGLAND</pp>
<sn>0022-2836; 0022-2836</sn>
<ad>Hearst Microbiology Research Center, Department of Microbiology, Cornell University Medical College, New York, NY 10021.</ad>
<an>PMID: 1850805; 0022-2836(91)90267-A [pii]</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>1850805</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1824</id>
<a1>Ward,P.</a1>
<a1>Dean,F. B.</a1>
<a1>O&#39;Donnell,M. E.</a1>
<a1>Berns,K. I.</a1>
<t1>Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1998</yr>
<fd>Jan</fd>
<vo>72</vo>
<is>1</is>
<sp>420</sp>
<op>427</op>
<k1>Adenoviridae/metabolism</k1>
<k1>DNA Replication/physiology</k1>
<k1>DNA, Single-Stranded/metabolism</k1>
<k1>DNA, Viral/biosynthesis</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/metabolism</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Plasmids/metabolism</k1>
<k1>Replication Protein A</k1>
<k1>Viral Proteins/metabolism</k1>
<ab>A basic question in adeno-associated virus (AAV) biology has been whether adenovirus (Ad) infection provided any function which directly promoted replication of AAV DNA. Previously in vitro assays for AAV DNA replication, using linear duplex AAV DNA as the template, uninfected or Ad-infected HeLa cell extracts, and exogenous AAV Rep protein, demonstrated that Ad infection provides a direct helper effect for AAV DNA replication. It was shown that the nature of this helper effect was to increase the processivity of AAV DNA replication. Left unanswered was the question of whether this effect was the result of cellular factors whose activity was enhanced by Ad infection or was the result of direct participation of Ad proteins in AAV DNA replication. In this report, we show that in the in vitro assay, enhancement of processivity occurs with the addition of either the Ad DNA-binding protein (Ad-DBP) or the human single-stranded DNA-binding protein (replication protein A [RPA]). Clearly Ad-DBP is present after Ad infection but not before, whereas the cellular level of RPA is not apparently affected by Ad infection. However, we have not measured possible modifications of RPA which might occur after Ad infection and affect AAV DNA replication. When the substrate for replication was an AAV genome inserted into a plasmid vector, RPA was not an effective substitute for Ad-DBP. Extracts supplemented with Ad-DBP preferentially replicated AAV sequences rather than adjacent vector sequences; in contrast, extracts supplemented with RPA preferentially replicated vector sequences.</ab>
<no>LR: 20091118; GR: GM50032/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (DBP protein, Adenovirus); 0 (DNA, Single-Stranded); 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (RPA1 protein, human); 0 (Replication Protein A); 0 (Viral Proteins); OID: NLM: PMC109390; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021, USA. pjward@mail.med.cornell.edu</ad>
<an>PMID: 9420241</an>
<la>eng</la>
<sf>Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>9420241</pmid>
<pmcid>PMC109390</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1838</id>
<a1>Ward,P.</a1>
<a1>Urcelay,E.</a1>
<a1>Kotin,R.</a1>
<a1>Safer,B.</a1>
<a1>Berns,K. I.</a1>
<t1>Adeno-associated virus DNA replication in vitro: activation by a maltose binding protein/Rep 68 fusion protein</t1>
<jf>Journal of virology</jf>
<jo>J.Virol.</jo>
<yr>1994</yr>
<fd>Sep</fd>
<vo>68</vo>
<is>9</is>
<sp>6029</sp>
<op>6037</op>
<k1>ATP-Binding Cassette Transporters</k1>
<k1>Carrier Proteins/metabolism</k1>
<k1>DNA Replication</k1>
<k1>DNA, Viral/metabolism</k1>
<k1>DNA-Binding Proteins/metabolism</k1>
<k1>Dependovirus/genetics</k1>
<k1>Escherichia coli Proteins</k1>
<k1>Gene Expression Regulation, Viral</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>Monosaccharide Transport Proteins</k1>
<k1>Recombinant Fusion Proteins/metabolism</k1>
<k1>Viral Proteins/metabolism</k1>
<k1>Virus Replication</k1>
<ab>The adeno-associated virus (AAV) nonstructural protein Rep 68 is required for viral DNA replication. An in vitro assay has been developed in which addition of Rep 68 to an extract from uninfected HeLa cells supports AAV DNA replication. In this paper, we report characterization of the replication process when a fusion of the maltose binding protein and Rep 68, expressed in Escherichia coli, was used in the assay. Replication was observed when the template was either linear double-stranded AAV DNA or a plasmid construct containing intact AAV DNA. When the recombinant plasmid construct was used as the template, there was replication of pBR322 DNA as well as the AAV DNA; however, linear pBR322 DNA was not replicated. When the plasmid construct was the template, replication appeared to initiate on the intact plasmid and led to separation of the AAV sequences from those of the vector, a process which has been termed rescue. There was no evidence that replication could initiate on the products of rescue. Rep 68 can make a site-specific nick 124 nucleotides from the 3&amp;#39; end of AAV DNA; the site of the nick has been called the terminal resolution site. Our data are most consistent with initiation occurring at the terminal resolution site and proceeding toward the 3&amp;#39; terminus. When the template was the plasmid construct, either elongation continued past the junction into pBR322 sequences or the newly synthesized sequence hairpinned, switched template strands, and replicated the AAV DNA. Replication was linear for 4 h, during which time 70% of the maximal synthesis took place. An additional finding was that the Rep fusion could resolve AAV dimer length duplex intermediates into monomer duplexes without DNA synthesis.</ab>
<no>LR: 20091118; GR: GM 50032/GM/NIGMS NIH HHS/United States; JID: 0113724; 0 (ATP-Binding Cassette Transporters); 0 (Carrier Proteins); 0 (DNA, Viral); 0 (DNA-Binding Proteins); 0 (Escherichia coli Proteins); 0 (Monosaccharide Transport Proteins); 0 (Recombinant Fusion Proteins); 0 (Viral Proteins); 0 (maltose transport system, E coli); 0 (maltose-binding protein); 137750-19-7 (rep proteins, Adeno-associated virus 2); OID: NLM: PMC237008; ppublish</no>
<pp>UNITED STATES</pp>
<sn>0022-538X; 0022-538X</sn>
<ad>Department of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, New York 10021.</ad>
<an>PMID: 8057478</an>
<la>eng</la>
<sf>In Vitro; Journal Article; Research Support, U.S. Gov&#39;t, P.H.S.; IM</sf>
<ol>Unknown(0)</ol>
<pmid>8057478</pmid>
<pmcid>PMC237008</pmcid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1794</id>
<a1>Wilson,J. M.</a1>
<a1>Gansbacher,B.</a1>
<a1>Berns,K. I.</a1>
<a1>Bosch,F.</a1>
<a1>Kay,M. A.</a1>
<a1>Naldini,L.</a1>
<a1>Wei,Y. Q.</a1>
<t1>Good news on the clinical gene transfer front</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2008</yr>
<fd>May</fd>
<vo>19</vo>
<is>5</is>
<sp>429</sp>
<op>430</op>
<k1>Gene Therapy</k1>
<k1>Gene Transfer Techniques</k1>
<k1>Humans</k1>
<k1>Optic Atrophy, Hereditary, Leber/therapy</k1>
<no>JID: 9008950; ppublish</no>
<pp>United States</pp>
<sn>1557-7422; 1043-0342</sn>
<an>PMID: 18507511</an>
<la>eng</la>
<sf>Editorial; IM</sf>
<do>10.1089/hum.2008.0519</do>
<ol>Unknown(0)</ol>
<pmid>18507511</pmid></reference>
<reference>
<rt>Journal Article</rt>
<sr> Print(0)</sr>
<id>1795</id>
<a1>Zhang,C.</a1>
<a1>Cortez,N. G.</a1>
<a1>Berns,K. I.</a1>
<t1>Characterization of a bipartite recombinant adeno-associated viral vector for site-specific integration</t1>
<jf>Human Gene Therapy</jf>
<jo>Hum.Gene Ther.</jo>
<yr>2007</yr>
<fd>Sep</fd>
<vo>18</vo>
<is>9</is>
<sp>787</sp>
<op>797</op>
<k1>Blotting, Southern</k1>
<k1>Chromosomes, Human, Pair 19</k1>
<k1>Clone Cells</k1>
<k1>DNA-Binding Proteins</k1>
<k1>Dependovirus/genetics/metabolism</k1>
<k1>Electrophoresis, Polyacrylamide Gel</k1>
<k1>Flow Cytometry</k1>
<k1>Genetic Vectors</k1>
<k1>Green Fluorescent Proteins/metabolism</k1>
<k1>Hela Cells</k1>
<k1>Humans</k1>
<k1>In Situ Hybridization, Fluorescence</k1>
<k1>Polymerase Chain Reaction</k1>
<k1>Recombination, Genetic</k1>
<k1>Transduction, Genetic</k1>
<k1>Transfection</k1>
<k1>Transgenes</k1>
<k1>Viral Proteins</k1>
<k1>Virus Integration</k1>
<ab>Adeno-associated virus type 2 (AAV2) is the only virus known to integrate into a specific locus in the human genome. The locus, AAVS1, is on the q arm of chromosome 19 at position 13.4. AAV is currently a popular vector for human gene therapy. However, current vectors do not contain two important elements needed for site-specific integration, that is, the rep gene or the P5 promoter, although they do integrate with low frequency at random locations in the human genome. We have designed a bipartite vector that does insert the transgene into AAVS1. One component, rAAVSVAV2, contains the rep gene, driven by the simian virus 40 early promoter rather than the P5 promoter. Thus, the integration enhancer element (IEE) within P5, which greatly enhances site-specific integration, has been deleted. The other component, rAAVP5UF11, contains the P5 IEE plus the transgene with associated regulatory elements. We have created clones of transduced HeLa cells, most of which appear to have the transgene inserted in AAVS1. We have not detected any clones that have rep inserted anywhere. With the optimal multiplicity of infection and ratio of rAAVSVAV2 and rAAVP5UF11, the transgene integrated specifically at AAVS1 with high efficiency (&amp;gt;60%). Most importantly, the cloned cell lines with the AAVS1 site-specific integrated green fluorescent protein (GFP) were healthy and stably expressed GFP for 35 passages. An AAV vector that would integrate at a specific site with high frequency could offer significant advantage in the transduction of progenitor cells and stem cells ex vivo and engineered cells could be used for human gene therapy. AAV site-specific integration gene therapy could provide a novel approach for diseases that need long-term gene expression.</ab>
<no>JID: 9008950; 0 (DNA-Binding Proteins); 0 (Viral Proteins); 137750-19-7 (rep proteins, Adeno-associated virus 2); 147336-22-9 (Green Fluorescent Proteins); ppublish</no>
<pp>United States</pp>
<sn>1043-0342; 1043-0342</sn>
<ad>Department of Molecular Genetics and Microbiology, Genetics Institute, University of Florida, Gainesville, FL 32610, USA.</ad>
<an>PMID: 17760515</an>
<la>eng</la>
<sf>Journal Article; Research Support, Non-U.S. Gov&#39;t; IM</sf>
<do>10.1089/hum.2007.056</do>
<ol>Unknown(0)</ol>
<pmid>17760515</pmid></reference></refworks>
